aminolevulinic acid has been researched along with Pain in 120 studies
Aminolevulinic Acid: A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS.
5-aminolevulinic acid : The simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp.
Pain: An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the efficacy of a new three-step irradiance schedule derived from the psychological "peak-end rule" and two-step irradiance schedule in relieving pain during 5-aminolevulinic acid PDT (ALA-PDT) on acne." | 9.51 | Three-step irradiance schedule versus two-step irradiance schedule for pain control during topical 5-aminolevulinic acid-photodynamic therapy of facial acne in Chinese patients: A prospective randomized comparative study. ( Cui, L; Liu, YB; Sun, XD; Wu, HE; Xu, GJ, 2022) |
| "Photodynamic therapy (PDT) with 5-aminolevulinic acid (ALA) has been described as an effective treatment for severe acne." | 9.34 | Photodynamic therapy for severe facial acne vulgaris with 5% 5-aminolevulinic acid vs 10% 5-aminolevulinic acid: A split-face randomized controlled study. ( He, Y; Huang, H; Huang, J; Lu, C; Wu, X; Zhang, J; Zhang, X, 2020) |
| "Aminolevulinic acid (ALA) photodynamic therapy (PDT) is an established treatment option for actinic keratosis (AK), and recently fractional carbon dioxide (CO2) laser was shown to improve outcomes; but studies of short incubation photosensitizer are lacking." | 9.24 | Randomized, Controlled Trial of Fractional Carbon Dioxide Laser Resurfacing Followed by Ultrashort Incubation Aminolevulinic Acid Blue Light Photodynamic Therapy for Actinic Keratosis. ( Alexiades, M, 2017) |
| "Photodynamic therapy (PDT) and chemical peels with trichloroacetic acid (TCA) can be applied to large skin areas and thus are suitable treatment options for patients with multiple actinic keratosis (AK)." | 9.24 | Randomized controlled trial comparing 35% trichloroacetic acid peel and 5-aminolaevulinic acid photodynamic therapy for treating multiple actinic keratosis. ( Holzer, G; Pinkowicz, A; Radakovic, S; Schmidt, JB; Tanew, A, 2017) |
| "Although aminolevulinic acid (ALA)-induced protoporphyrin IX (PpIX) photodynamic therapy (PDT) is an effective FDA-approved therapy for actinic keratosis (AK), a substantial fraction of patients (up to 25%) do not respond to treatment." | 9.20 | Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy. ( Chapman, MS; Davis, SC; Hasan, T; Kanick, SC; Maytin, EV; Pogue, BW; Sheehan, KL; Zhao, Y, 2015) |
| "To determine pain intensity and its dependence upon various factors during PDT with 5-aminolevulinic acid for face/scalp AKs." | 9.17 | Pain during topical photodynamic therapy of actinic keratoses with 5-aminolevulinic acid and red light source: randomized controlled trial. ( Buinauskaite, E; Buinauskiene, J; Valiukeviciene, S; Zalinkevicius, R, 2013) |
| "To determine the impact of skin pretreatment with microneedles (MNs) on ALA- and MAL-induced protoporphyrin IX (PpIX) production, as well as MN impact on pain sensations during light exposure and erythema after PDT." | 9.14 | Microneedle pre-treatment of human skin improves 5-aminolevulininc acid (ALA)- and 5-aminolevulinic acid methyl ester (MAL)-induced PpIX production for topical photodynamic therapy without increase in pain or erythema. ( Donnelly, RF; Garland, MJ; Iani, V; Juzeniene, A; Mikolajewska, P; Moan, J; Morrow, DI; Singh, TR, 2010) |
| "To compare the pain experienced in normal skin treated with 5-aminolevulinic acid (ALA) PDT and 5-aminolevulinic methylester (ALA-ME) PDT." | 9.10 | Pain associated with photodynamic therapy using 5-aminolevulinic acid or 5-aminolevulinic acid methylester on tape-stripped normal skin. ( Na, R; Stender, IM; Wiegell, SR; Wulf, HC, 2003) |
| "Pain during topical aminolevulinic acid (ALA)-mediated photodynamic therapy (PDT) limits the use of this treatment of skin diseases." | 8.85 | Pain associated with aminolevulinic acid-photodynamic therapy of skin disease. ( Karai, LJ; Maytin, EV; Vidimos, A; Warren, CB, 2009) |
| "We assessed whether PDT clinical outcome and pain during treatment were correlated with protoporphyrin IX fluorescence intensity and photobleaching." | 7.79 | Correlation between protoporphyrin IX fluorescence intensity, photobleaching, pain and clinical outcome of actinic keratosis treated by photodynamic therapy. ( Barge, J; Kasraee, B; Piffaretti, F; Salomon, D; van den Bergh, H; Wagnières, G; Zellweger, M, 2013) |
| "In superficial basal cell carcinomas treated with photodynamic therapy with topical delta-aminolevulinic acid, we examined effects of light irradiance on photodynamic efficiency and pain." | 7.74 | Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas. ( Cottrell, WJ; Foster, TH; Keymel, KR; Oseroff, AR; Paquette, AD, 2008) |
| "Photodynamic therapy with topical delta-aminolevulinic acid using approximately 40 mW/cm(2) at 633 nm is photodynamically efficient with minimum pain." | 7.74 | Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas. ( Cottrell, WJ; Foster, TH; Keymel, KR; Oseroff, AR; Paquette, AD, 2008) |
| "Acne vulgaris is a chronic inflammatory skin disease, commonly treated with topical or systemic drugs, according to the severity of the condition." | 6.90 | The efficacy and tolerability of 5-aminolevulinic acid 5% thermosetting gel photodynamic therapy (PDT) in the treatment of mild-to-moderate acne vulgaris. A two-center, prospective assessor-blinded, proof-of-concept study. ( Bianchi, L; Campione, E; Cannizzaro, MV; Dattola, A; Del Duca, E; Garofalo, V; Milani, M; Serini, SM; Ventura, A, 2019) |
| "However, pain was not an exclusive indicator of PpIX concentration as many patients with low PpIX concentration reported high pain." | 6.80 | Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy. ( Chapman, MS; Davis, SC; Hasan, T; Kanick, SC; Maytin, EV; Pogue, BW; Sheehan, KL; Zhao, Y, 2015) |
| "The pain was dominated by characteristics such as burning and pricking and was almost always local and superficial." | 6.79 | Two-step irradiance schedule versus single-dose tramadol sustained-release tablets for pain control during topical 5-aminolevulinic acid-photodynamic therapy of condyloma acuminatum in Chinese patients: a randomized comparative study. ( Huang, CY; Mchepange, UO; Sun, Y; Tao, J; Tu, YT, 2014) |
| "The pain was moderate in both groups and peaked earlier in the analgesics group (median: 5 minutes) but later in the two-step irradiance group (median: 15 minutes)." | 6.79 | Two-step irradiance schedule versus single-dose tramadol sustained-release tablets for pain control during topical 5-aminolevulinic acid-photodynamic therapy of condyloma acuminatum in Chinese patients: a randomized comparative study. ( Huang, CY; Mchepange, UO; Sun, Y; Tao, J; Tu, YT, 2014) |
| "The pain was generally mild." | 6.79 | Two-step irradiance schedule versus single-dose tramadol sustained-release tablets for pain control during topical 5-aminolevulinic acid-photodynamic therapy of condyloma acuminatum in Chinese patients: a randomized comparative study. ( Huang, CY; Mchepange, UO; Sun, Y; Tao, J; Tu, YT, 2014) |
| "Pain is the major drawback of photodynamic therapy (PDT), an otherwise effective treatment for actinic keratoses (AKs)." | 6.78 | Pain during topical photodynamic therapy of actinic keratoses with 5-aminolevulinic acid and red light source: randomized controlled trial. ( Buinauskaite, E; Buinauskiene, J; Valiukeviciene, S; Zalinkevicius, R, 2013) |
| "Pain was independent of the patient's Fitzpatrick skin type, AK clinical grade, pretreatment fluorescence intensity, and the light dose during PDT." | 6.78 | Pain during topical photodynamic therapy of actinic keratoses with 5-aminolevulinic acid and red light source: randomized controlled trial. ( Buinauskaite, E; Buinauskiene, J; Valiukeviciene, S; Zalinkevicius, R, 2013) |
| "Although PDT is a well-tolerated treatment, pain is the most severe side effect." | 6.72 | Photodynamic therapy induces less pain in patients treated with methyl aminolevulinate compared to aminolevulinic acid. ( Hein, R; Kasche, A; Luderschmidt, S; Ring, J, 2006) |
| "Pain was assessed pre-illumination, during, and immediately after illumination, using a numeric rating scale." | 6.72 | Morphine gel 0.3% does not relieve pain during topical photodynamic therapy: a randomized, double-blind, placebo-controlled study. ( Haedersdal, M; Philipsen, PA; Skiveren, J; Wiegell, SR; Wulf, HC, 2006) |
| "Pain was scored using a numerical scale ranging from 0 to 10 during illumination, immediately after illumination, and each day in the following week." | 6.71 | Pain associated with photodynamic therapy using 5-aminolevulinic acid or 5-aminolevulinic acid methylester on tape-stripped normal skin. ( Na, R; Stender, IM; Wiegell, SR; Wulf, HC, 2003) |
| "Photodynamic therapy (PDT) with 5-aminolevulinic acid (ALA) is a reliable treatment for actinic keratosis (AK), but its effect needs to be enhanced in thick lesions." | 5.69 | Plum-blossom needle tapping enhances the efficacy of ALA photodynamic therapy for facial actinic keratosis in Chinese population: a randomized, multicenter, prospective, and observer-blind study. ( Chen, Z; Lei, X; Li, D; Li, Y; Lu, Y; Shen, S; Wang, P; Wang, X; Xiao, R; Xie, F; Zeng, W; Zhang, G; Zhang, L; Zhao, S; Zhu, L, 2023) |
| "To evaluate the efficacy of a new three-step irradiance schedule derived from the psychological "peak-end rule" and two-step irradiance schedule in relieving pain during 5-aminolevulinic acid PDT (ALA-PDT) on acne." | 5.51 | Three-step irradiance schedule versus two-step irradiance schedule for pain control during topical 5-aminolevulinic acid-photodynamic therapy of facial acne in Chinese patients: A prospective randomized comparative study. ( Cui, L; Liu, YB; Sun, XD; Wu, HE; Xu, GJ, 2022) |
| "Pain was monitored." | 5.35 | Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas. ( Cottrell, WJ; Foster, TH; Keymel, KR; Oseroff, AR; Paquette, AD, 2008) |
| "When PpIX was 90% bleached, irradiance was increased to 150 mW/cm(2) until 200 J/cm(2) were delivered." | 5.35 | Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas. ( Cottrell, WJ; Foster, TH; Keymel, KR; Oseroff, AR; Paquette, AD, 2008) |
| "Once PpIX is largely photobleached, higher irradiances allow efficient, rapid delivery of additional light." | 5.35 | Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas. ( Cottrell, WJ; Foster, TH; Keymel, KR; Oseroff, AR; Paquette, AD, 2008) |
| ") Key secondary end points were levels of ALA and porphobilinogen and the annualized attack rate among patients with acute hepatic porphyria, along with hemin use and daily worst pain scores in patients with acute intermittent porphyria." | 5.34 | Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria. ( Anderson, KE; Balwani, M; Bissell, DM; Bonkovsky, HL; Chen, J; Garg, P; Gouya, L; Harper, P; Horie, Y; Ivanova, A; Kauppinen, R; Keel, SB; Kim, JB; Ko, JJ; Langendonk, JG; Liu, S; Minder, E; Parker, C; Peiró, PA; Penz, C; Phillips, J; Rees, DC; Sardh, E; Silver, SM; Simon, AR; Stein, PE; Stölzel, U; Sweetser, MT; Vaishnaw, A; Vassiliou, D; Ventura, P; Wang, B; Wang, JD; Windyga, J, 2020) |
| " Among the patients with acute intermittent porphyria, givosiran led to lower levels of urinary ALA and porphobilinogen, fewer days of hemin use, and better daily scores for pain than placebo." | 5.34 | Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria. ( Anderson, KE; Balwani, M; Bissell, DM; Bonkovsky, HL; Chen, J; Garg, P; Gouya, L; Harper, P; Horie, Y; Ivanova, A; Kauppinen, R; Keel, SB; Kim, JB; Ko, JJ; Langendonk, JG; Liu, S; Minder, E; Parker, C; Peiró, PA; Penz, C; Phillips, J; Rees, DC; Sardh, E; Silver, SM; Simon, AR; Stein, PE; Stölzel, U; Sweetser, MT; Vaishnaw, A; Vassiliou, D; Ventura, P; Wang, B; Wang, JD; Windyga, J, 2020) |
| "Photodynamic therapy (PDT) with 5-aminolevulinic acid (ALA) has been described as an effective treatment for severe acne." | 5.34 | Photodynamic therapy for severe facial acne vulgaris with 5% 5-aminolevulinic acid vs 10% 5-aminolevulinic acid: A split-face randomized controlled study. ( He, Y; Huang, H; Huang, J; Lu, C; Wu, X; Zhang, J; Zhang, X, 2020) |
| "Aminolevulinic acid (ALA) photodynamic therapy (PDT) is an established treatment option for actinic keratosis (AK), and recently fractional carbon dioxide (CO2) laser was shown to improve outcomes; but studies of short incubation photosensitizer are lacking." | 5.24 | Randomized, Controlled Trial of Fractional Carbon Dioxide Laser Resurfacing Followed by Ultrashort Incubation Aminolevulinic Acid Blue Light Photodynamic Therapy for Actinic Keratosis. ( Alexiades, M, 2017) |
| "Photodynamic therapy (PDT) and chemical peels with trichloroacetic acid (TCA) can be applied to large skin areas and thus are suitable treatment options for patients with multiple actinic keratosis (AK)." | 5.24 | Randomized controlled trial comparing 35% trichloroacetic acid peel and 5-aminolaevulinic acid photodynamic therapy for treating multiple actinic keratosis. ( Holzer, G; Pinkowicz, A; Radakovic, S; Schmidt, JB; Tanew, A, 2017) |
| "Although aminolevulinic acid (ALA)-induced protoporphyrin IX (PpIX) photodynamic therapy (PDT) is an effective FDA-approved therapy for actinic keratosis (AK), a substantial fraction of patients (up to 25%) do not respond to treatment." | 5.20 | Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy. ( Chapman, MS; Davis, SC; Hasan, T; Kanick, SC; Maytin, EV; Pogue, BW; Sheehan, KL; Zhao, Y, 2015) |
| " Objective and visual erythema, protoporphyrin IX (PpIX) fluorescence and pain were evaluated." | 5.19 | Topical corticosteroid reduces inflammation without compromising the efficacy of photodynamic therapy for actinic keratoses: a randomized clinical trial. ( Petersen, B; Wiegell, SR; Wulf, HC, 2014) |
| "To determine pain intensity and its dependence upon various factors during PDT with 5-aminolevulinic acid for face/scalp AKs." | 5.17 | Pain during topical photodynamic therapy of actinic keratoses with 5-aminolevulinic acid and red light source: randomized controlled trial. ( Buinauskaite, E; Buinauskiene, J; Valiukeviciene, S; Zalinkevicius, R, 2013) |
| " The secondary objectives were to compare the two treatments regarding pain, detection of substance P, change in fluorescence intensity from before to 5 h after cream application and adverse events not related to local phototoxicity." | 5.14 | Phototoxic reactions in healthy volunteers following photodynamic therapy with methylaminolevulinate cream or with cream containing 5-aminolevulinic acid: a phase II, randomized study. ( Ackermann, G; Babilas, P; Karrer, S; Landthaler, M; Schreml, S; Steinbauer, J; Szeimies, RM, 2009) |
| "To determine the impact of skin pretreatment with microneedles (MNs) on ALA- and MAL-induced protoporphyrin IX (PpIX) production, as well as MN impact on pain sensations during light exposure and erythema after PDT." | 5.14 | Microneedle pre-treatment of human skin improves 5-aminolevulininc acid (ALA)- and 5-aminolevulinic acid methyl ester (MAL)-induced PpIX production for topical photodynamic therapy without increase in pain or erythema. ( Donnelly, RF; Garland, MJ; Iani, V; Juzeniene, A; Mikolajewska, P; Moan, J; Morrow, DI; Singh, TR, 2010) |
| "To evaluate the efficacy and safety of LPDL alone versus LPDL in photodynamic therapy with methylaminolevulinic acid (MAL-LPDL) for acne vulgaris." | 5.13 | Long-pulsed dye laser versus long-pulsed dye laser-assisted photodynamic therapy for acne vulgaris: A randomized controlled trial. ( Haedersdal, M; Togsverd-Bo, K; Wiegell, SR; Wulf, HC, 2008) |
| "To compare the pain experienced in normal skin treated with 5-aminolevulinic acid (ALA) PDT and 5-aminolevulinic methylester (ALA-ME) PDT." | 5.10 | Pain associated with photodynamic therapy using 5-aminolevulinic acid or 5-aminolevulinic acid methylester on tape-stripped normal skin. ( Na, R; Stender, IM; Wiegell, SR; Wulf, HC, 2003) |
| "Pain during topical aminolevulinic acid (ALA)-mediated photodynamic therapy (PDT) limits the use of this treatment of skin diseases." | 4.85 | Pain associated with aminolevulinic acid-photodynamic therapy of skin disease. ( Karai, LJ; Maytin, EV; Vidimos, A; Warren, CB, 2009) |
| "The acute hepatic porphyrias (AHPs) are inherited disorders of heme biosynthesis characterized by life-threatening acute neurovisceral attacks precipitated by factors that upregulate hepatic 5-aminolevulinic acid synthase 1 (ALAS1) activity." | 4.31 | RNA interference therapy in acute hepatic porphyrias. ( Balwani, M; Keel, S; Yasuda, M, 2023) |
| "The efficacy of photodynamic therapy (PDT) using topical 5-aminolevulinic acid (ALA) for the treatment of actinic keratosis (AKs) is lower on the distal extremities compared with the head and neck areas." | 3.80 | Temperature-modulated photodynamic therapy for the treatment of actinic keratosis on the extremities: a pilot study. ( Anderson, RR; Sakamoto, FH; Willey, A, 2014) |
| "We assessed whether PDT clinical outcome and pain during treatment were correlated with protoporphyrin IX fluorescence intensity and photobleaching." | 3.79 | Correlation between protoporphyrin IX fluorescence intensity, photobleaching, pain and clinical outcome of actinic keratosis treated by photodynamic therapy. ( Barge, J; Kasraee, B; Piffaretti, F; Salomon, D; van den Bergh, H; Wagnières, G; Zellweger, M, 2013) |
| "Photodynamic therapy (PDT) with topical δ-aminolevulinic acid (ALA) of non-melanoma skin cancers is often associated with treatment-limiting pain." | 3.79 | A retrospective review of pain control by a two-step irradiance schedule during topical ALA-photodynamic therapy of non-melanoma skin cancer. ( Foster, TH; Henderson, BW; Housel, JP; Paquette, AD; Shi, Y; Wilding, GE; Zeitouni, NC, 2013) |
| "Because of the retrospective study design not all factors that may influence pain (eg, protoporphyrin IX fluorescence) were recorded." | 3.76 | Factors influencing pain intensity during topical photodynamic therapy of complete cosmetic units for actinic keratoses. ( Denk, K; Enk, A; Gholam, P; Hartmann, M; Sehr, T, 2010) |
| "In superficial basal cell carcinomas treated with photodynamic therapy with topical delta-aminolevulinic acid, we examined effects of light irradiance on photodynamic efficiency and pain." | 3.74 | Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas. ( Cottrell, WJ; Foster, TH; Keymel, KR; Oseroff, AR; Paquette, AD, 2008) |
| "Photodynamic therapy with topical delta-aminolevulinic acid using approximately 40 mW/cm(2) at 633 nm is photodynamically efficient with minimum pain." | 3.74 | Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas. ( Cottrell, WJ; Foster, TH; Keymel, KR; Oseroff, AR; Paquette, AD, 2008) |
| " A provisional diagnosis of acute intermittent porphyria was made and was confirmed by the increased levels of urinary delta-aminolevulinic acid (ALA) and porphobilinogen (PBG)." | 3.68 | Acute intermittent porphyria. A perplexing case. ( Arena, A; Russo, P; Scuderi, D, 1992) |
| "However, pain was significantly lower in the combPDT group (2." | 3.11 | Combined versus conventional photodynamic therapy with 5-aminolaevulinic acid nanoemulsion (BF-200 ALA) for actinic keratosis: A randomized, single-blind, prospective study. ( Cuenca-Barrales, C; Linares-Gonzalez, L; Molina-Leyva, A; Ródenas-Herranz, T; Ruiz-Villaverde, R; Sáenz-Guirado, S; Vega-Castillo, J, 2022) |
| "Pain is a frequent adverse event during photodynamic therapy, which can limit treatment acceptance." | 3.11 | Randomized controlled trial for evaluation of efficacy and pain during photodynamic therapy for actinic keratosis of face and scalp comparing two irradiation protocols. ( Ag, S; Er, O; Ha, M; Lpf, A; Mb, R; Mmc, M; Mr, G, 2022) |
| "However, pain and hypertension are important side effects of conventional PDT (c-PDT)." | 3.11 | Hemodynamic changes during conventional and daylight photodynamic therapy of actinic keratoses - a randomized controlled trial. ( Enk, A; Gholam, P; Hartmann, J; Keller, A, 2022) |
| "Pain was quantified using a visual analog scale." | 3.11 | Hemodynamic changes during conventional and daylight photodynamic therapy of actinic keratoses - a randomized controlled trial. ( Enk, A; Gholam, P; Hartmann, J; Keller, A, 2022) |
| "Pain was evaluated on a scale from 0 to 10." | 2.94 | A regimen to minimize pain during blue light photodynamic therapy of actinic keratoses: Bilaterally controlled, randomized trial of simultaneous versus conventional illumination. ( Bullock, T; Hu, B; Ilyas, M; Kaw, U; Maytin, EV; Riha, M; Rittwage, L; Vidimos, A; Warren, CB, 2020) |
| "5-aminolevulinic acid (ALA; 20 %) was incubated for 3 h before patients were exposed to LED red light (100 J/cm2) on the C-PDT side and for 30 min before being exposed to LED red light (300 J/cm2) on the M-PDT side." | 2.94 | Modified photodynamic therapy to minimize pain in the treatment of condylomata acuminata: A prospective, randomized, self-controlled study. ( Cao, Y; Shi, L; Wang, P; Wang, X; Zhang, G; Zhang, H; Zhang, Y; Zhou, Z, 2020) |
| "Pain is a major concern associated with conventional photodynamic therapy (C-PDT)." | 2.94 | Modified photodynamic therapy to minimize pain in the treatment of condylomata acuminata: A prospective, randomized, self-controlled study. ( Cao, Y; Shi, L; Wang, P; Wang, X; Zhang, G; Zhang, H; Zhang, Y; Zhou, Z, 2020) |
| "Acne vulgaris is a chronic inflammatory skin disease, commonly treated with topical or systemic drugs, according to the severity of the condition." | 2.90 | The efficacy and tolerability of 5-aminolevulinic acid 5% thermosetting gel photodynamic therapy (PDT) in the treatment of mild-to-moderate acne vulgaris. A two-center, prospective assessor-blinded, proof-of-concept study. ( Bianchi, L; Campione, E; Cannizzaro, MV; Dattola, A; Del Duca, E; Garofalo, V; Milani, M; Serini, SM; Ventura, A, 2019) |
| "Pain was significantly higher during the second session (p = 0." | 2.90 | Single versus two-treatment schedule of methyl aminolevulinate daylight photodynamic therapy for actinic keratosis of the face and scalp: An intra-patient randomized trial. ( Fargnoli, MC; Gutiérrez García-Rodrigo, C; Pellegrini, C; Piccioni, A; Tambone, S, 2019) |
| "Severe acne vulgaris has limited therapeutic options." | 2.82 | Photodynamic therapy with methyl aminolaevulinate 80 mg g(-1) for severe facial acne vulgaris: a randomized vehicle-controlled study. ( Bukhalo, M; Eichenfield, LF; Jarratt, M; Pariser, DM; Waterman, G, 2016) |
| "Pain was low and manageable by briefly pausing illumination." | 2.82 | Photodynamic therapy with methyl aminolaevulinate 80 mg g(-1) for severe facial acne vulgaris: a randomized vehicle-controlled study. ( Bukhalo, M; Eichenfield, LF; Jarratt, M; Pariser, DM; Waterman, G, 2016) |
| "Aminolevulinic acid or VEH was applied to face or scalp as a broad area application for 1, 2, or 3 hours or as a spot application for 2 hours before blue light activation." | 2.82 | Randomized Vehicle-Controlled Study of Short Drug Incubation Aminolevulinic Acid Photodynamic Therapy for Actinic Keratoses of the Face or Scalp. ( Berg, JE; Ferdon, MB; Houlihan, A; Pariser, DM, 2016) |
| "However, pain is a major side-effect of this therapy." | 2.80 | Comparing cold-air analgesia, systemically administered analgesia and scalp nerve blocks for pain management during photodynamic therapy for actinic keratosis of the scalp presenting as field cancerization: a randomized controlled trial. ( Graf, B; Gruber, M; Hansen, E; Heinlin, J; Horner, C; Karrer, S; Kerscher, C; Klein, A; Koller, M; Landthaler, M; Szeimies, RM; Werner, A; Zeman, F, 2015) |
| "Maximum pain was evaluated by means of a visual analogue scale (VAS) during and up to 300 min after PDT." | 2.80 | Comparing cold-air analgesia, systemically administered analgesia and scalp nerve blocks for pain management during photodynamic therapy for actinic keratosis of the scalp presenting as field cancerization: a randomized controlled trial. ( Graf, B; Gruber, M; Hansen, E; Heinlin, J; Horner, C; Karrer, S; Kerscher, C; Klein, A; Koller, M; Landthaler, M; Szeimies, RM; Werner, A; Zeman, F, 2015) |
| "However, pain was not an exclusive indicator of PpIX concentration as many patients with low PpIX concentration reported high pain." | 2.80 | Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy. ( Chapman, MS; Davis, SC; Hasan, T; Kanick, SC; Maytin, EV; Pogue, BW; Sheehan, KL; Zhao, Y, 2015) |
| "The pain was dominated by characteristics such as burning and pricking and was almost always local and superficial." | 2.79 | Two-step irradiance schedule versus single-dose tramadol sustained-release tablets for pain control during topical 5-aminolevulinic acid-photodynamic therapy of condyloma acuminatum in Chinese patients: a randomized comparative study. ( Huang, CY; Mchepange, UO; Sun, Y; Tao, J; Tu, YT, 2014) |
| "The pain was moderate in both groups and peaked earlier in the analgesics group (median: 5 minutes) but later in the two-step irradiance group (median: 15 minutes)." | 2.79 | Two-step irradiance schedule versus single-dose tramadol sustained-release tablets for pain control during topical 5-aminolevulinic acid-photodynamic therapy of condyloma acuminatum in Chinese patients: a randomized comparative study. ( Huang, CY; Mchepange, UO; Sun, Y; Tao, J; Tu, YT, 2014) |
| "The pain was generally mild." | 2.79 | Two-step irradiance schedule versus single-dose tramadol sustained-release tablets for pain control during topical 5-aminolevulinic acid-photodynamic therapy of condyloma acuminatum in Chinese patients: a randomized comparative study. ( Huang, CY; Mchepange, UO; Sun, Y; Tao, J; Tu, YT, 2014) |
| "The main side-effects of PDT are post-treatment erythema and oedema, and pain during illumination." | 2.79 | Topical corticosteroid reduces inflammation without compromising the efficacy of photodynamic therapy for actinic keratoses: a randomized clinical trial. ( Petersen, B; Wiegell, SR; Wulf, HC, 2014) |
| "Pain was measured using a visual analog scale immediately and 8 h after PDT." | 2.78 | Dermatology life quality index and side effects after topical photodynamic therapy of actinic keratosis. ( Enk, AH; Gholam, P; Kroehl, V, 2013) |
| "Pain is the major drawback of photodynamic therapy (PDT), an otherwise effective treatment for actinic keratoses (AKs)." | 2.78 | Pain during topical photodynamic therapy of actinic keratoses with 5-aminolevulinic acid and red light source: randomized controlled trial. ( Buinauskaite, E; Buinauskiene, J; Valiukeviciene, S; Zalinkevicius, R, 2013) |
| "Pain was independent of the patient's Fitzpatrick skin type, AK clinical grade, pretreatment fluorescence intensity, and the light dose during PDT." | 2.78 | Pain during topical photodynamic therapy of actinic keratoses with 5-aminolevulinic acid and red light source: randomized controlled trial. ( Buinauskaite, E; Buinauskiene, J; Valiukeviciene, S; Zalinkevicius, R, 2013) |
| "Pain is a major side effect thereof, and it affects the treatment compliance and acceptance." | 2.78 | Correlations between photoactivable porphyrins' fluorescence, erythema and the pain induced by PDT on normal skin using ALA-derivatives. ( Barge, J; Glanzmann, T; Salomon, D; van den Bergh, H; Wagnières, G; Zellweger, M, 2013) |
| "minor improvement, P = 0·007) than PDT-treated skin." | 2.77 | Intensified photodynamic therapy of actinic keratoses with fractional CO2 laser: a randomized clinical trial. ( Anderson, RR; Haak, CS; Hædersdal, M; Hædesdal, M; Thaysen-Petersen, D; Togsverd-Bo, K; Wulf, HC, 2012) |
| "MAL was applied 3 h before light treatment." | 2.75 | Photodynamic therapy of multiple actinic keratoses: reduced pain through use of visible light plus water-filtered infrared A compared with light from light-emitting diodes. ( Abuzahra, F; Braathen, LR; Hoff-Lesch, S; Hoffmann, G; Merk, HF; Renn, CN; von Felbert, V, 2010) |
| "Pain was assessed before, during and after PDT." | 2.75 | Photodynamic therapy of multiple actinic keratoses: reduced pain through use of visible light plus water-filtered infrared A compared with light from light-emitting diodes. ( Abuzahra, F; Braathen, LR; Hoff-Lesch, S; Hoffmann, G; Merk, HF; Renn, CN; von Felbert, V, 2010) |
| "Pain was assessed by the patient using a visual analog scale directly after treatment." | 2.73 | Effect of subcutaneous infiltration anesthesia on pain in photodynamic therapy: a controlled open pilot trial. ( Berking, C; Borelli, C; Degitz, K; Herzinger, T; Kunte, C; Merk, K; Plewig, G, 2007) |
| "Pain was assessed using a visual analogue scale at 3, 6, 12 and 16 min." | 2.73 | Randomized, double-blind, prospective study to compare topical 5-aminolaevulinic acid methylester with topical 5-aminolaevulinic acid photodynamic therapy for extensive scalp actinic keratosis. ( Collins, P; Moloney, FJ, 2007) |
| "Although PDT is a well-tolerated treatment, pain is the most severe side effect." | 2.72 | Photodynamic therapy induces less pain in patients treated with methyl aminolevulinate compared to aminolevulinic acid. ( Hein, R; Kasche, A; Luderschmidt, S; Ring, J, 2006) |
| "Pain was assessed pre-illumination, during, and immediately after illumination, using a numeric rating scale." | 2.72 | Morphine gel 0.3% does not relieve pain during topical photodynamic therapy: a randomized, double-blind, placebo-controlled study. ( Haedersdal, M; Philipsen, PA; Skiveren, J; Wiegell, SR; Wulf, HC, 2006) |
| "Pain was scored using a numerical scale ranging from 0 to 10 during illumination, immediately after illumination, and each day in the following week." | 2.71 | Pain associated with photodynamic therapy using 5-aminolevulinic acid or 5-aminolevulinic acid methylester on tape-stripped normal skin. ( Na, R; Stender, IM; Wiegell, SR; Wulf, HC, 2003) |
| "Pain was assessed using a linear analogue scale from 0 to 10." | 2.70 | Photodynamic therapy for superficial bladder cancer under local anaesthetic. ( Betts, CD; Briggs, C; Clarke, NW; Gilhooley, A; Moore, JV; O'Flynn, KJ; Shackley, DC; Whitehurst, C, 2002) |
| "Actinic cheilitis is difficult to treat because surgical treatments have significant adverse effects whereas less invasive procedures have uncertain efficacy." | 2.52 | Photodynamic therapy for actinic cheilitis: a systematic review. ( Falto-Aizpurua, L; Griffith, RD; Nouri, K; Yazdani Abyaneh, MA, 2015) |
| "However, PDT pain is multifactorial and choice of photosensitiser is probably not a major pain determining factor." | 2.47 | A review of pain experienced during topical photodynamic therapy--our experience in Dundee. ( Attili, SK; Dawe, R; Ibbotson, S, 2011) |
| "The acute hepatic porphyrias (AHPs) are inherited disorders of heme biosynthesis characterized by life-threatening acute neurovisceral attacks precipitated by factors that upregulate hepatic 5-aminolevulinic acid synthase 1 (ALAS1) activity." | 1.91 | RNA interference therapy in acute hepatic porphyrias. ( Balwani, M; Keel, S; Yasuda, M, 2023) |
| " This prospective open-label observational single-arm study examined efficacy and safety of simulated daylight (SDL)-PDT using the IndoorLux® system in combination with 5-aminolevulinic acid gel (BF-200 ALA)." | 1.72 | No room for pain: A prospective study showing effective and nearly pain-free treatment of actinic keratosis with simulated daylight photodynamic therapy (SDL-PDT) using the IndoorLux® System in combination with BF-200 ALA (Ameluz®). ( Bai-Habelski, JC; Medrano, K; Palacio, A; Reinhold, U, 2022) |
| "Acne vulgaris is a chronic inflammatory skin disease around pilosebaceous unit." | 1.72 | A prospective study of adverse reactions of ALA-PDT for acne vulgaris. ( Liu, X; Shi, L; Wang, P; Wang, X; Yan, G; Yang, J; Zhang, G; Zhang, H; Zhang, L; Zhang, Y; Zhou, Z, 2022) |
| "Referral skin cancer centre in Australia." | 1.42 | Post procedural pain with photodynamic therapy is more severe than skin surgery. ( Anderson, SJ; Dixon, AJ; Dixon, JB; Dixon, MP, 2015) |
| "Pain was assessed after the PDT session and local adverse events 2 days after treatment." | 1.42 | Conventional vs. daylight methyl aminolevulinate photodynamic therapy for actinic keratosis of the face and scalp: an intra-patient, prospective, comparison study in Italy. ( Fargnoli, MC; Neri, L; Pellegrini, C; Peris, K; Piccioni, A; Tambone, S, 2015) |
| "46%; RR = 0." | 1.42 | Conventional vs. daylight methyl aminolevulinate photodynamic therapy for actinic keratosis of the face and scalp: an intra-patient, prospective, comparison study in Italy. ( Fargnoli, MC; Neri, L; Pellegrini, C; Peris, K; Piccioni, A; Tambone, S, 2015) |
| "Pain was assessed using a visual analog scale (VAS)." | 1.39 | A retrospective review of pain control by a two-step irradiance schedule during topical ALA-photodynamic therapy of non-melanoma skin cancer. ( Foster, TH; Henderson, BW; Housel, JP; Paquette, AD; Shi, Y; Wilding, GE; Zeitouni, NC, 2013) |
| "Pain was strongly influenced by lesion location but not by lesion type, number, or size." | 1.39 | A retrospective review of pain control by a two-step irradiance schedule during topical ALA-photodynamic therapy of non-melanoma skin cancer. ( Foster, TH; Henderson, BW; Housel, JP; Paquette, AD; Shi, Y; Wilding, GE; Zeitouni, NC, 2013) |
| "Two of three Bowen's disease lesions showed a complete response." | 1.39 | A retrospective review of pain control by a two-step irradiance schedule during topical ALA-photodynamic therapy of non-melanoma skin cancer. ( Foster, TH; Henderson, BW; Housel, JP; Paquette, AD; Shi, Y; Wilding, GE; Zeitouni, NC, 2013) |
| "Pain is one of the major adverse effects." | 1.37 | Treatment with 5-aminolaevulinic acid methylester is less painful than treatment with 5-aminolaevulinic acid nanoemulsion in topical photodynamic therapy for actinic keratosis. ( Denk, K; Enk, A; Gholam, P; Weberschock, T, 2011) |
| "Pain was rated using a standardized visual analogue scale (VAS)." | 1.37 | Treatment with 5-aminolaevulinic acid methylester is less painful than treatment with 5-aminolaevulinic acid nanoemulsion in topical photodynamic therapy for actinic keratosis. ( Denk, K; Enk, A; Gholam, P; Weberschock, T, 2011) |
| "We present a case of an anaplastic astrocytoma (WHO-grade III, AA III) in a 27-year-old woman treated by spinal cordectomy." | 1.36 | Cordectomy as final treatment option for diffuse intramedullary malignant glioma using 5-ALA fluorescence-guided resection. ( Ewelt, C; Felsberg, J; Klink, B; Sabel, M; Steiger, HJ; Stummer, W, 2010) |
| "Eight hours after treatment the mean pain +/- SEM in all locations was reduced significantly (P < ." | 1.36 | Factors influencing pain intensity during topical photodynamic therapy of complete cosmetic units for actinic keratoses. ( Denk, K; Enk, A; Gholam, P; Hartmann, M; Sehr, T, 2010) |
| "Pain is one of the major adverse effects during and after the treatment." | 1.36 | Factors influencing pain intensity during topical photodynamic therapy of complete cosmetic units for actinic keratoses. ( Denk, K; Enk, A; Gholam, P; Hartmann, M; Sehr, T, 2010) |
| "Pain was rated using a visual analog scale directly and 8 hours after photodynamic therapy." | 1.36 | Factors influencing pain intensity during topical photodynamic therapy of complete cosmetic units for actinic keratoses. ( Denk, K; Enk, A; Gholam, P; Hartmann, M; Sehr, T, 2010) |
| "Pain was monitored." | 1.35 | Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas. ( Cottrell, WJ; Foster, TH; Keymel, KR; Oseroff, AR; Paquette, AD, 2008) |
| "When PpIX was 90% bleached, irradiance was increased to 150 mW/cm(2) until 200 J/cm(2) were delivered." | 1.35 | Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas. ( Cottrell, WJ; Foster, TH; Keymel, KR; Oseroff, AR; Paquette, AD, 2008) |
| "Once PpIX is largely photobleached, higher irradiances allow efficient, rapid delivery of additional light." | 1.35 | Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas. ( Cottrell, WJ; Foster, TH; Keymel, KR; Oseroff, AR; Paquette, AD, 2008) |
| "Pain was assessed during illumination using a continuous visual analogue scale (VAS)." | 1.35 | Topical photodynamic therapy with porphyrin precursors--assessment of treatment-associated pain in a retrospective study. ( Babilas, P; Karrer, S; Landthaler, M; Schreml, S; Steinbauer, JM; Szeimies, RM; Zeman, F, 2009) |
| "The main adverse effect in PDT treatment is pain." | 1.34 | Pain and photodynamic therapy. ( Brogaard, HM; Jemec, GB; Lindeburg, KE, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (1.67) | 18.7374 |
| 1990's | 3 (2.50) | 18.2507 |
| 2000's | 23 (19.17) | 29.6817 |
| 2010's | 66 (55.00) | 24.3611 |
| 2020's | 26 (21.67) | 2.80 |
| Authors | Studies |
|---|---|
| Wojewoda, K | 1 |
| Gillstedt, M | 1 |
| Tovi, J | 1 |
| Salah, L | 1 |
| Wennberg Larkö, AM | 1 |
| Sjöholm, A | 1 |
| Sandberg, C | 4 |
| Sáenz-Guirado, S | 1 |
| Cuenca-Barrales, C | 1 |
| Vega-Castillo, J | 1 |
| Linares-Gonzalez, L | 1 |
| Ródenas-Herranz, T | 1 |
| Molina-Leyva, A | 1 |
| Ruiz-Villaverde, R | 1 |
| Er, O | 1 |
| Ag, S | 1 |
| Ha, M | 1 |
| Mb, R | 1 |
| Mmc, M | 1 |
| Mr, G | 1 |
| Lpf, A | 1 |
| Bai-Habelski, JC | 1 |
| Medrano, K | 1 |
| Palacio, A | 1 |
| Reinhold, U | 2 |
| Keller, A | 3 |
| Hartmann, J | 3 |
| Enk, A | 4 |
| Gholam, P | 6 |
| Shi, L | 3 |
| Yang, J | 2 |
| Zhang, L | 3 |
| Zhang, Y | 3 |
| Yan, G | 1 |
| Zhang, H | 3 |
| Liu, X | 1 |
| Wang, P | 4 |
| Zhang, G | 4 |
| Zhou, Z | 3 |
| Wang, X | 4 |
| Lonsdorf, AS | 2 |
| Enk, AH | 2 |
| Chen, K | 1 |
| Huang, Q | 1 |
| Xu, L | 1 |
| Hu, JS | 1 |
| Yang, MY | 1 |
| Chen, JB | 1 |
| Li, DS | 1 |
| Wulf, HC | 14 |
| Heerfordt, IM | 3 |
| Silic, K | 1 |
| Kammer, M | 1 |
| Sator, PG | 1 |
| Tanew, A | 2 |
| Radakovic, S | 3 |
| Yasuda, M | 1 |
| Keel, S | 1 |
| Balwani, M | 2 |
| Xie, F | 1 |
| Zhao, S | 1 |
| Zhu, L | 1 |
| Shen, S | 1 |
| Li, D | 1 |
| Chen, Z | 1 |
| Xiao, R | 1 |
| Lu, Y | 1 |
| Lei, X | 1 |
| Li, Y | 1 |
| Zeng, W | 1 |
| Bhatia, N | 1 |
| Kaw, U | 1 |
| Ilyas, M | 1 |
| Bullock, T | 1 |
| Rittwage, L | 1 |
| Riha, M | 1 |
| Vidimos, A | 2 |
| Hu, B | 1 |
| Warren, CB | 2 |
| Maytin, EV | 3 |
| Hellen, R | 1 |
| Nic Dhonncha, E | 1 |
| Havelin, A | 1 |
| Fleming, L | 1 |
| Kavanagh, A | 1 |
| Lally, A | 1 |
| Kirby, B | 1 |
| Moriarty, B | 1 |
| Collins, P | 2 |
| Salido-Vallejo, R | 1 |
| Jiménez-Nájar, F | 1 |
| Garnacho-Sucedo, G | 1 |
| Vélez, A | 1 |
| Lecamwasam, K | 1 |
| Skellett, AM | 1 |
| Levell, NJ | 1 |
| Marcus, S | 1 |
| Sardh, E | 1 |
| Ventura, P | 1 |
| Peiró, PA | 1 |
| Rees, DC | 1 |
| Stölzel, U | 1 |
| Bissell, DM | 1 |
| Bonkovsky, HL | 1 |
| Windyga, J | 1 |
| Anderson, KE | 1 |
| Parker, C | 1 |
| Silver, SM | 1 |
| Keel, SB | 1 |
| Wang, JD | 1 |
| Stein, PE | 1 |
| Harper, P | 1 |
| Vassiliou, D | 1 |
| Wang, B | 1 |
| Phillips, J | 1 |
| Ivanova, A | 1 |
| Langendonk, JG | 1 |
| Kauppinen, R | 1 |
| Minder, E | 1 |
| Horie, Y | 1 |
| Penz, C | 1 |
| Chen, J | 1 |
| Liu, S | 1 |
| Ko, JJ | 1 |
| Sweetser, MT | 1 |
| Garg, P | 1 |
| Vaishnaw, A | 1 |
| Kim, JB | 1 |
| Simon, AR | 1 |
| Gouya, L | 1 |
| Cao, Y | 1 |
| Wu, HE | 2 |
| Liu, YB | 2 |
| Cui, L | 2 |
| Qin, P | 1 |
| Xu, GJ | 2 |
| Sun, XD | 2 |
| Han, XW | 1 |
| Salvio, AG | 1 |
| Stringasci, MD | 1 |
| Requena, MB | 1 |
| de Oliveira, ER | 1 |
| da Costa Medeiro, MM | 1 |
| Bagnato, VS | 1 |
| Hobelsberger, S | 1 |
| Krauß, MP | 1 |
| Bogdan, C | 1 |
| Aschoff, R | 1 |
| Alexiades, M | 1 |
| Petukhova, TA | 1 |
| Hassoun, LA | 1 |
| Foolad, N | 1 |
| Barath, M | 1 |
| Sivamani, RK | 2 |
| Togsverd-Bo, K | 4 |
| Halldin, C | 1 |
| Gonzalez, H | 1 |
| Wennberg, AM | 4 |
| Sørensen, SS | 1 |
| Haedersdal, M | 4 |
| Kessels, JPHM | 1 |
| Kreukels, H | 1 |
| Nelemans, PJ | 2 |
| Roozeboom, MH | 1 |
| van Pelt, H | 1 |
| Mosterd, K | 2 |
| de Haas, ERM | 1 |
| Kelleners-Smeets, NWJ | 1 |
| Torezan, L | 1 |
| Grinblat, B | 1 |
| Valente, N | 1 |
| Festa-Neto, C | 1 |
| Szeimies, RM | 9 |
| Philipp-Dormston, WG | 2 |
| Rybarski, M | 1 |
| Schmitz, L | 1 |
| Novak, B | 1 |
| Dirschka, T | 3 |
| Serini, SM | 1 |
| Cannizzaro, MV | 1 |
| Dattola, A | 1 |
| Garofalo, V | 1 |
| Del Duca, E | 1 |
| Ventura, A | 1 |
| Milani, M | 1 |
| Campione, E | 1 |
| Bianchi, L | 1 |
| Osiecka, BJ | 1 |
| Nockowski, P | 1 |
| Szepietowski, JC | 1 |
| Rioli, DI | 1 |
| Samimi, M | 1 |
| Beneton, N | 1 |
| Hainaut, E | 1 |
| Martin, L | 1 |
| Misery, L | 1 |
| Quereux, G | 1 |
| Serra-Guillén, C | 2 |
| Nagore, E | 1 |
| Bancalari, E | 1 |
| Kindem, S | 1 |
| Sanmartín, O | 1 |
| Llombart, B | 1 |
| Requena, C | 1 |
| Serra-Guillén, I | 1 |
| Calomarde, L | 1 |
| Diago, A | 1 |
| Bernia, E | 1 |
| Guillén, C | 1 |
| Mei, X | 1 |
| Wang, L | 1 |
| Zhang, R | 1 |
| Zhong, S | 1 |
| Willey, A | 2 |
| Gutiérrez García-Rodrigo, C | 1 |
| Pellegrini, C | 2 |
| Piccioni, A | 2 |
| Tambone, S | 2 |
| Fargnoli, MC | 2 |
| Borroni, RG | 1 |
| Carugno, A | 1 |
| Rivetti, N | 1 |
| Arbustini, E | 1 |
| Brazzelli, V | 1 |
| Dixon, AJ | 1 |
| Anderson, SJ | 1 |
| Dixon, MP | 1 |
| Dixon, JB | 1 |
| Kroehl, V | 1 |
| Buinauskaite, E | 1 |
| Zalinkevicius, R | 1 |
| Buinauskiene, J | 1 |
| Valiukeviciene, S | 1 |
| Middelburg, TA | 1 |
| Nijsten, T | 1 |
| Neumann, MH | 1 |
| de Haas, ER | 1 |
| Robinson, DJ | 1 |
| Piffaretti, F | 1 |
| Zellweger, M | 2 |
| Kasraee, B | 1 |
| Barge, J | 2 |
| Salomon, D | 2 |
| van den Bergh, H | 2 |
| Wagnières, G | 2 |
| Basset-Seguin, N | 3 |
| Glanzmann, T | 1 |
| Huang, N | 1 |
| Zeng, J | 1 |
| Liang, J | 1 |
| Qiu, H | 1 |
| Wang, Y | 1 |
| Gu, Y | 1 |
| Mchepange, UO | 1 |
| Huang, CY | 1 |
| Sun, Y | 1 |
| Tu, YT | 1 |
| Tao, J | 1 |
| Rubel, DM | 1 |
| Spelman, L | 1 |
| Murrell, DF | 1 |
| See, JA | 1 |
| Hewitt, D | 1 |
| Foley, P | 2 |
| Bosc, C | 1 |
| Kerob, D | 1 |
| Kerrouche, N | 2 |
| Shumack, S | 1 |
| Lei, U | 1 |
| Erlendsson, AM | 1 |
| Taudorf, EH | 1 |
| Philipsen, PA | 3 |
| Skov, L | 1 |
| Hædersdal, M | 2 |
| Wiegell, SR | 7 |
| Petersen, B | 2 |
| Anderson, RR | 2 |
| Sakamoto, FH | 1 |
| Klein, A | 1 |
| Karrer, S | 5 |
| Horner, C | 1 |
| Werner, A | 1 |
| Heinlin, J | 1 |
| Zeman, F | 2 |
| Koller, M | 1 |
| Landthaler, M | 4 |
| Gruber, M | 1 |
| Graf, B | 1 |
| Hansen, E | 1 |
| Kerscher, C | 1 |
| Yazdani Abyaneh, MA | 1 |
| Falto-Aizpurua, L | 1 |
| Griffith, RD | 1 |
| Nouri, K | 1 |
| Oh, CC | 1 |
| Theng, TS | 1 |
| Chong, WS | 1 |
| Neri, L | 1 |
| Peris, K | 1 |
| Lerche, CM | 1 |
| Fabricius, S | 1 |
| Neittaanmäki-Perttu, N | 1 |
| Neittaanmäki, E | 1 |
| Pölönen, I | 1 |
| Snellman, E | 1 |
| Grönroos, M | 1 |
| Lacour, JP | 2 |
| Ulrich, C | 2 |
| Gilaberte, Y | 1 |
| Von Felbert, V | 2 |
| Dreno, B | 2 |
| Girard, C | 2 |
| Redondo, P | 1 |
| Synnerstad, I | 1 |
| Tarstedt, M | 1 |
| Tsianakas, A | 1 |
| Venema, AW | 1 |
| Kelleners-Smeets, N | 1 |
| Adamski, H | 2 |
| Perez-Garcia, B | 1 |
| Gerritsen, MJ | 1 |
| Leclerc, S | 1 |
| Kanick, SC | 1 |
| Davis, SC | 1 |
| Zhao, Y | 1 |
| Sheehan, KL | 1 |
| Hasan, T | 1 |
| Pogue, BW | 1 |
| Chapman, MS | 1 |
| Kessels, JP | 1 |
| Kelleners-Smeets, NW | 1 |
| Krekels, GA | 1 |
| Ostertag, JU | 1 |
| Berneburg, M | 1 |
| Petering, H | 1 |
| Berking, C | 3 |
| Gerber, PA | 1 |
| Hunger, RE | 1 |
| Pariser, DM | 2 |
| Eichenfield, LF | 1 |
| Bukhalo, M | 1 |
| Waterman, G | 1 |
| Jarratt, M | 1 |
| Houlihan, A | 1 |
| Ferdon, MB | 1 |
| Berg, JE | 1 |
| Beaulieu, P | 1 |
| Riboulet, JL | 1 |
| Nissen, CV | 1 |
| Mikkelsen, CS | 1 |
| Lev-Tov, H | 1 |
| Larsen, L | 1 |
| Zackria, R | 1 |
| Chahal, H | 1 |
| Eisen, DB | 1 |
| Holzer, G | 1 |
| Pinkowicz, A | 1 |
| Schmidt, JB | 1 |
| Hambly, RA | 1 |
| Mansoor, N | 1 |
| Quinlan, C | 1 |
| Shah, Z | 1 |
| Lenane, P | 1 |
| Ralph, N | 1 |
| Moloney, FJ | 2 |
| Gandy, J | 1 |
| Labadie, B | 1 |
| Bierman, D | 1 |
| Zachary, C | 1 |
| Campbell, SM | 1 |
| Morton, CA | 1 |
| Alyahya, R | 1 |
| Horton, S | 1 |
| Pye, A | 1 |
| Curnow, A | 1 |
| Cottrell, WJ | 1 |
| Paquette, AD | 2 |
| Keymel, KR | 1 |
| Foster, TH | 2 |
| Oseroff, AR | 1 |
| Fai, D | 1 |
| Arpaia, N | 1 |
| Romano, I | 1 |
| Vestita, M | 1 |
| Cassano, N | 1 |
| Vena, GA | 1 |
| Steinbauer, JM | 1 |
| Schreml, S | 2 |
| Babilas, P | 3 |
| Steinbauer, J | 1 |
| Ackermann, G | 1 |
| Mikolajewska, P | 2 |
| Iani, V | 2 |
| Juzeniene, A | 2 |
| Moan, J | 2 |
| Karai, LJ | 1 |
| Ewelt, C | 1 |
| Stummer, W | 1 |
| Klink, B | 1 |
| Felsberg, J | 1 |
| Steiger, HJ | 1 |
| Sabel, M | 1 |
| Hoffmann, G | 1 |
| Hoff-Lesch, S | 1 |
| Abuzahra, F | 1 |
| Renn, CN | 1 |
| Braathen, LR | 1 |
| Merk, HF | 1 |
| Denk, K | 2 |
| Sehr, T | 1 |
| Hartmann, M | 1 |
| Donnelly, RF | 1 |
| Garland, MJ | 1 |
| Morrow, DI | 1 |
| Singh, TR | 1 |
| García-Morales, I | 1 |
| Harto, A | 1 |
| Fernández-Guarino, M | 1 |
| Jaén, P | 1 |
| Palm, MD | 1 |
| Goldman, MP | 1 |
| Attili, SK | 1 |
| Dawe, R | 1 |
| Ibbotson, S | 2 |
| Apalla, Z | 1 |
| Sotiriou, E | 1 |
| Panagiotidou, D | 1 |
| Lefaki, I | 1 |
| Goussi, C | 1 |
| Ioannides, D | 1 |
| Weberschock, T | 1 |
| Radny, P | 1 |
| Dominicus, R | 1 |
| Mensing, H | 1 |
| Brüning, H | 1 |
| Jenne, L | 1 |
| Karl, L | 1 |
| Sebastian, M | 1 |
| Oster-Schmidt, C | 1 |
| Klövekorn, W | 1 |
| Tanner, M | 1 |
| Gröne, D | 1 |
| Deichmann, M | 1 |
| Simon, M | 1 |
| Hübinger, F | 1 |
| Hofbauer, G | 1 |
| Krähn-Senftleben, G | 1 |
| Borrosch, F | 1 |
| Reich, K | 1 |
| Wolf, P | 2 |
| Lehmann, P | 1 |
| Moers-Carpi, M | 1 |
| Hönigsmann, H | 1 |
| Wernicke-Panten, K | 1 |
| Helwig, C | 1 |
| Foguet, M | 1 |
| Schmitz, B | 1 |
| Lübbert, H | 1 |
| Gaál, M | 2 |
| Otrosinka, S | 1 |
| Baltás, E | 1 |
| Ocsai, H | 1 |
| Oláh, J | 1 |
| Kemény, L | 2 |
| Gyulai, R | 2 |
| Haak, CS | 1 |
| Thaysen-Petersen, D | 1 |
| Hædesdal, M | 1 |
| Kui, R | 1 |
| Hunyadi, Z | 1 |
| Ibbotson, SH | 1 |
| Valentine, R | 1 |
| Hearn, R | 1 |
| Hong, JS | 1 |
| Jung, JY | 1 |
| Yoon, JY | 1 |
| Suh, DH | 1 |
| Zeitouni, NC | 1 |
| Housel, JP | 1 |
| Shi, Y | 1 |
| Wilding, GE | 1 |
| Henderson, BW | 1 |
| Stender, IM | 1 |
| Na, R | 1 |
| Ericson, MB | 2 |
| Stenquist, B | 1 |
| Gudmundson, F | 1 |
| Karlsson, M | 1 |
| Ros, AM | 1 |
| Rosén, A | 1 |
| Larkö, O | 1 |
| Rosdahl, I | 1 |
| Kohl, E | 1 |
| Maisch, T | 1 |
| Bäcker, H | 1 |
| Gross, B | 1 |
| Branzan, AL | 1 |
| Bäumler, W | 1 |
| Kasche, A | 1 |
| Luderschmidt, S | 1 |
| Ring, J | 1 |
| Hein, R | 1 |
| Moseley, H | 1 |
| Woods, J | 1 |
| Brancaleon, L | 1 |
| Lesar, A | 1 |
| Goodman, C | 1 |
| Ferguson, J | 1 |
| Skiveren, J | 1 |
| Borelli, C | 1 |
| Herzinger, T | 1 |
| Merk, K | 1 |
| Kunte, C | 1 |
| Plewig, G | 1 |
| Degitz, K | 1 |
| Lindeburg, KE | 1 |
| Brogaard, HM | 1 |
| Jemec, GB | 1 |
| Halldin, CB | 1 |
| Paoli, J | 1 |
| Edwards, S | 1 |
| Jackson, D | 1 |
| Reynoldson, J | 1 |
| Shanley, B | 1 |
| Fink-Puches, R | 1 |
| Hofer, A | 1 |
| Smolle, J | 1 |
| Kerl, H | 1 |
| Martin-Hirsch, P | 1 |
| Kitchener, HC | 1 |
| Hampson, IN | 1 |
| Shackley, DC | 1 |
| Briggs, C | 1 |
| Gilhooley, A | 1 |
| Whitehurst, C | 1 |
| O'Flynn, KJ | 1 |
| Betts, CD | 1 |
| Moore, JV | 1 |
| Clarke, NW | 1 |
| Irwig, LM | 1 |
| Harrison, WO | 1 |
| Rocks, P | 1 |
| Webster, I | 1 |
| Andrew, M | 1 |
| Arena, A | 1 |
| Russo, P | 1 |
| Scuderi, D | 1 |
| Mitchell, G | 1 |
| Larochelle, J | 1 |
| Lambert, M | 1 |
| Michaud, J | 1 |
| Grenier, A | 1 |
| Ogier, H | 1 |
| Gauthier, M | 1 |
| Lacroix, J | 1 |
| Vanasse, M | 1 |
| Larbrisseau, A | 1 |
| Zhang, J | 1 |
| Zhang, X | 1 |
| He, Y | 1 |
| Wu, X | 1 |
| Huang, J | 1 |
| Huang, H | 1 |
| Lu, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| ENVISION: A Phase 3 Randomized, Double-blind, Placebo-Controlled Multicenter Study With an Open-label Extension to Evaluate the Efficacy and Safety of Givosiran in Patients With Acute Hepatic Porphyrias[NCT03338816] | Phase 3 | 94 participants (Actual) | Interventional | 2017-11-16 | Completed | ||
| The Use of Microneedles to Expedite Treatment Time in Photodynamic Therapy[NCT02594644] | 32 participants (Actual) | Interventional | 2014-11-06 | Completed | |||
| Clinical Effect of Photodynamic Treatment When Treating Actinic Keratoses With Different Light Doses[NCT01541228] | 38 participants (Actual) | Interventional | 2010-04-30 | Completed | |||
| Indoor Daylight Photo Dynamic Therapy (PDT) for Actinic Keratosis[NCT03805737] | 43 participants (Actual) | Interventional | 2019-11-01 | Completed | |||
| Portable Measurement of Protoporphyrin IX in the Skin[NCT04223570] | 218 participants (Anticipated) | Observational | 2022-12-01 | Enrolling by invitation | |||
| A Randomized, Observer Blind, Multinational Phase III Study to Evaluate the Safety and Efficacy of a Nanoemulsion Gel Formulation BF-200 ALA, in Comparison With Metvix® and Placebo, for the Treatment of Actinic Keratosis With PDT[NCT02799069] | Phase 3 | 571 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Fractional Carbon Dioxide Laser Assisted Delivery of Topical Anesthetics: a Randomized Controlled Pilot Study[NCT02246179] | Phase 4 | 10 participants (Actual) | Interventional | 2014-09-30 | Completed | ||
| Fractional CO2 Laser Assisted Topical Articaine Anesthesia vs. Topical EMLA Administration: a Randomized Controlled Study[NCT02548533] | Phase 4 | 3 participants (Actual) | Interventional | 2015-06-30 | Terminated (stopped due to Not enough patients eligible for recruitment.) | ||
| Evaluation of the Formulation of 5-aminolevulinic Acid With Dimethylsulfoxide in Photodynamic Therapy for Treatment of Actinic Keratosis[NCT01459393] | Phase 3 | 137 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Annualized rate of hemin doses was evaluated as annualized days of hemin use. (NCT03338816)
Timeframe: 6 months
| Intervention | annualized rate of use (Mean) |
|---|---|
| Placebo | 29.71 |
| Givosiran 2.5 mg/kg | 6.77 |
Porphyria attacks were defined as meeting all of the following criteria: an acute episode of neurovisceral pain in the abdomen, back, chest, extremities and/or limbs, no other medically determined cause, and required treatment with intravenous (IV) dextrose or hemin, carbohydrates, or analgesics, or other medications such as antiemetics at a dose or frequency beyond the participant's usual daily porphyria management. The annualized rate of porphyria attacks is a composite endpoint which included porphyria attacks requiring hospitalization, urgent healthcare visit, or IV hemin administration at home. (NCT03338816)
Timeframe: 6 months
| Intervention | annualized attack rate (Mean) |
|---|---|
| Placebo | 12.52 |
| Givosiran 2.5 mg/kg | 3.22 |
Porphyria attacks were defined as meeting all of the following criteria: an acute episode of neurovisceral pain in the abdomen, back, chest, extremities and/or limbs, no other medically determined cause, and required treatment with intravenous (IV) dextrose or hemin, carbohydrates, or analgesics, or other medications such as antiemetics at a dose or frequency beyond the participant's usual daily porphyria management. The annualized rate of porphyria attacks is a composite endpoint which included porphyria attacks requiring hospitalization, urgent healthcare visit, or IV hemin administration at home. (NCT03338816)
Timeframe: 6 months
| Intervention | annualized attack rate (Mean) |
|---|---|
| Placebo | 12.26 |
| Givosiran 2.5 mg/kg | 3.35 |
Participants rated worst daily pain score in an eDiary using the 11-point BPI-SF NRS, in which 0=no pain and 10=worst pain. Daily eDiary entries were averaged into a weekly (i.e. 7 day) score. The change from baseline in weekly mean scores is defined as the post baseline weekly mean score minus the baseline score. Lower scores indicate an improvement. The 6-month AUC was calculated based on change from baseline in weekly mean scores. (NCT03338816)
Timeframe: Baseline and 6 months
| Intervention | score on a scale*week (Median) |
|---|---|
| Placebo | 5.286 |
| Givosiran 2.5 mg/kg | -11.514 |
Participants rated worst daily nausea score in an eDiary using an 11-point NRS, in which 0=no nausea and 10=worst nausea. Daily eDiary entries were averaged into a weekly (i.e. 7 day) score. The change from baseline in weekly mean scores is defined as the postbaseline weekly mean score minus the baseline score. Lower scores indicate an improvement. The 6-month AUC was calculated based on change from baseline in weekly mean scores. (NCT03338816)
Timeframe: Baseline and 6 months
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Placebo | -4.011 |
| Givosiran 2.5 mg/kg | 1.481 |
Participants rated daily worst fatigue score in an eDiary using the 11-point BFI-SF NRS, in which 0=no fatigue and 10=worst fatigue. Daily eDiary entries were averaged into a weekly (i.e. 7 day) score. The change from baseline in weekly mean scores is defined as the post baseline weekly mean score minus the baseline score. Lower scores indicate an improvement. The 6-month AUC was calculated based on change from baseline in weekly mean scores. (NCT03338816)
Timeframe: Baseline and 6 months
| Intervention | score on a scale*week (Least Squares Mean) |
|---|---|
| Placebo | -4.208 |
| Givosiran 2.5 mg/kg | -11.148 |
Participants rated worst daily nausea score in an eDiary using an 11-point NRS, in which 0=no nausea and 10=worst nausea. Daily eDiary entries were averaged into a weekly (i.e. 7 day) score. The change from baseline in weekly mean scores is defined as the postbaseline weekly mean score minus the baseline score. Lower scores indicate an improvement. (NCT03338816)
Timeframe: Baseline and 6 months
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Placebo | -0.181 |
| Givosiran 2.5 mg/kg | 0.067 |
Participants rated daily worst fatigue score in an eDiary using the 11-point BFI-SF NRS, in which 0=no fatigue and 10=worst fatigue. Daily eDiary entries were averaged into a weekly (i.e. 7 day) score. The change from baseline in weekly mean scores is defined as the postbaseline weekly mean score minus the baseline score. Lower scores indicate an improvement. (NCT03338816)
Timeframe: Baseline and 6 months
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Placebo | -0.182 |
| Givosiran 2.5 mg/kg | -0.502 |
Participants rated worst daily pain score in an eDiary using the 11-point BPI-SF NRS, in which 0=no pain and 10=worst pain. Daily eDiary entries were averaged into a weekly (i.e. 7 day) score. The change from baseline in weekly mean scores is defined as the postbaseline weekly mean score minus the baseline score. Lower scores indicate an improvement. (NCT03338816)
Timeframe: Baseline and 6 months
| Intervention | score on a scale (Median) |
|---|---|
| Placebo | 0.245 |
| Givosiran 2.5 mg/kg | -0.506 |
The SF-12 is a survey designed for use in patients with multiple chronic conditions. This 12-item scale can be used to assess the physical and mental health of respondents. 10 of the 12 questions are answered on a 5 point likert scale and 2 are answered on a 3 point likert scale. The questions are then scored and weighted into 2 subscales, physical health and mental health. Respondents can have a score that ranges from 0-100 with 100 being the best score and indicating high physical or mental health. A 3 point change in SF-12 score reflects a meaningful difference. A higher score indicates improvement. (NCT03338816)
Timeframe: Baseline and 6 months
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Placebo | 1.431 |
| Givosiran 2.5 mg/kg | 5.369 |
The PD effect of givosiran was evaluated by spot urine PBG levels normalized to spot urine creatinine levels. (NCT03338816)
Timeframe: 6 months
| Intervention | mmol/mol Cr (Least Squares Mean) |
|---|---|
| Placebo | 49.110 |
| Givosiran 2.5 mg/kg | 12.906 |
The PD effect of givosiran was evaluated by spot urine ALA levels normalized to spot urine creatinine levels. (NCT03338816)
Timeframe: 3 and 6 months
| Intervention | mmol/mol creatinine (Cr) (Least Squares Mean) | |
|---|---|---|
| Month 3 | Month 6 | |
| Givosiran 2.5 mg/kg | 1.756 | 4.013 |
| Placebo | 19.965 | 23.150 |
The primary endpoint will be the difference in the percentage of complete clearance of the actinic keratoses as an intraindividual comparison between the treatment groups. (NCT02594644)
Timeframe: Baseline, 2 Months
| Intervention | Percentage of AK Clearance (Mean) |
|---|---|
| 10-minute Incubation With Microneedle Roller | 43 |
| 20-minute Incubation With Microneedle Roller | 76 |
| 10-minute Incubation With Sham Microneedles | 38 |
| 20-minute Incubation With Sham Microneedles | 58 |
"The secondary will be any pain associated with the microneedle pretreatment and with the application of the PDT using the 100 mm Visual Analog Scale pain grading. Using a ruler, the score is determined by measuring the distance (mm) on the 10-cm line between the no pain anchor and the patient's mark, providing a range of scores from 0-100. A higher score indicates greater pain intensity." (NCT02594644)
Timeframe: Immediately Post-Treatment
| Intervention | Millimeters (Mean) |
|---|---|
| Pain_microneedle: 10-minute Incubation With Microneedle Roller | 1.4 |
| Pain_microneedle: 20-minute Incubation With Microneedle Roller | 1.3 |
| Pain_microneedle: 10-minute Incubation With Microneedle Sham | .3 |
| Pain_microneedle: 20-minute Incubation With Microneedle Sham | .3 |
| Pain_PDT: 10-minute Incubation With Microneedle Sham | 0.3 |
| Pain_PDT: 10-minute Incubation With Microneedle Roller | .5 |
| Pain_PDT: 20-minute Incubation With Microneedle Sham | 0.4 |
| Pain_PDT: 20-minute Incubation With Microneedle Roller | .7 |
the change from baseline in the lesion area of all treated lesions per subject (summation of sizes of all treated lesions) assessed at 12 weeks after last PDT, combining the changes from baseline in total lesion area at 12 weeks after the first PDT and at 12 weeks after the second PDT (a second PDT was applied to subjects with non- or partially responding lesions 12 weeks after the first PDT). (NCT02799069)
Timeframe: 12 weeks after the last PDT, up to 24 weeks after the first treatment
| Intervention | percentage of change from baseline (Mean) |
|---|---|
| Vehicle | -48.5 |
| BF-200 ALA | -95.0 |
| MAL Cream | -92.0 |
the change from baseline in the lesion area of all treated lesions per subject (summation of sizes of all treated lesions) assessed 12 weeks after the second PDT. A second PDT was applied in case of non- or partially responding lesions 12 weeks after first PDT. (NCT02799069)
Timeframe: 12 weeks after the second PDT, 24 after first treatment
| Intervention | percentage of change from baseline (Mean) |
|---|---|
| Vehicle | -50.1 |
| BF-200 ALA | -92.3 |
| MAL Cream | -88.9 |
the change from baseline in the lesion area of all treated lesions per subject (summation of sizes of all treated lesions) assessed 12 weeks after the first PDT. (NCT02799069)
Timeframe: 12 weeks after the first PDT
| Intervention | percentage of change from baseline (Mean) |
|---|---|
| Vehicle | -37.0 |
| BF-200 ALA | -85.4 |
| MAL Cream | -80.9 |
the change from baseline in the lesion area of all treated lesions per subject (summation of sizes of all treated lesions) assessed at 3-4 weeks after last PDT, combining the changes from baseline in total lesion area of subjects 3-4 weeks after first PDT and second PDT (a second PDT was applied for subjects who showed non- or partially responding lesions 12 weeks after the first PDT). (NCT02799069)
Timeframe: 3-4 weeks after the last PDT, up to 16 weeks after the first treatment
| Intervention | percentage of change from baseline (Mean) |
|---|---|
| Vehicle | -43.8 |
| BF-200 ALA | -89.4 |
| MAL Cream | -86.6 |
Percentage of change from baseline in the lesion area of all treated lesions per subject (summation of sizes of all treated lesions) assessed at 3-4 weeks after the first PDT. (NCT02799069)
Timeframe: 3-4 weeks after the first PDT
| Intervention | percentage of change from baseline (Mean) |
|---|---|
| Vehicle | -26.9 |
| BF-200 ALA | -78.9 |
| MAL Cream | -75.7 |
the change from baseline in the lesion area of all treated lesions per subject (summation of sizes of all treated lesions) assessed 3-4 weeks after the second PDT. A second PDT was applied in case of non or partially responding lesions 12 weeks after first PDT. (NCT02799069)
Timeframe: 3-4 weeks after the second PDT, 15-16 weeks after first treatment
| Intervention | percentage of change from baseline (Mean) |
|---|---|
| Vehicle | -46.2 |
| BF-200 ALA | -91.4 |
| MAL Cream | -87.5 |
Completely cleared individual lesions as defined at 12 weeks after the first photodynamic therapy (PDT). (NCT02799069)
Timeframe: 12 weeks after the first PDT
| Intervention | percentage of lesions (Number) |
|---|---|
| Vehicle | 24.7 |
| BF-200 ALA | 73.8 |
| MAL Cream | 66.5 |
Completely cleared individual lesions 12 weeks after last PDT comprising of completely cleared individual lesions 12 weeks after the first or second PDT (a second PDT was applied in case individual lesions show no or partial response 12 weeks after first PDT). (NCT02799069)
Timeframe: 12 weeks after the last PDT, up to 24 weeks after first treatment
| Intervention | percentage of lesions (Number) |
|---|---|
| Vehicle | 37.1 |
| BF-200 ALA | 90.4 |
| MAL Cream | 83.2 |
Completely cleared individual lesions as defined at 12 weeks after second PDT. A second PDT was applied in case the individual lesion showed no or partial response 12 weeks after first PDT. (NCT02799069)
Timeframe: 12 weeks after the second PDT, 24 weeks after first treatment
| Intervention | percentage of lesions (Number) |
|---|---|
| Vehicle | 22.0 |
| BF-200 ALA | 69.3 |
| MAL Cream | 58.0 |
Completely cleared individual lesions as defined at 3-4 weeks after first photodynamic therapy (PDT) (NCT02799069)
Timeframe: 3-4 weeks after the first PDT
| Intervention | percentage of lesions (Number) |
|---|---|
| Vehicle | 12.7 |
| BF-200 ALA | 63.9 |
| MAL Cream | 58.8 |
Completely cleared individual lesions defined at 3-4 weeks after the last PDT comprising of completely cleared individual lesions 3-4 weeks after the first and after the second PDT (a second PDT was applied in case lesions show no or partial response 12 weeks after the first PDT). (NCT02799069)
Timeframe: 3-4 weeks after the last PDT, up to 16 weeks after first treatment
| Intervention | percentage of lesions (Number) |
|---|---|
| Vehicle | 31.4 |
| BF-200 ALA | 79.0 |
| MAL Cream | 73.5 |
Completely cleared individual lesions as defined at 3-4 weeks after the second PDT. A second PDT was applied in case the individual lesion showed no or partial response12 weeks after first PDT. (NCT02799069)
Timeframe: 3-4 weeks after the second PDT, 15-16 weeks after first treatment
| Intervention | percentage of lesions (Number) |
|---|---|
| Vehicle | 16.3 |
| BF-200 ALA | 60.4 |
| MAL Cream | 54.8 |
"Completely cleared individual lesions 12 weeks after last PDT comprising of individual cleared lesions 12 weeks after the first or second PDT. A second PDT was applied in case individual lesion showed no or partial response 12 weeks after the first PDT.~Lesions were illuminated during photodynamic therapy with narrow spectrum devices only (~630 nm)." (NCT02799069)
Timeframe: up to 12 weeks after the last PDT, up to 24 weeks after first treatment
| Intervention | percentage of lesions (Number) |
|---|---|
| Vehicle | 32.5 |
| BF-200 ALA | 93.6 |
| MAL Cream | 89.3 |
Pain (11-point numeric rating scale) by PDT Session; Overall (If both areas have been treated, maximum intensity over both areas is used for analysis.) Patients assessed the pain experienced during PDT using an 11-point numeric rating pain scale (NRPS) ranging from 0 (no pain at all) to 10 (worst possible pain). This score reflects the patient's maximum pain during PDT. This outcome measure shows pain score after the first PDT. (NCT02799069)
Timeframe: during PDT treatment [3 h - 4 h ]
| Intervention | units on a scale (Mean) |
|---|---|
| Vehicle | 0.5 |
| BF-200 ALA | 4.4 |
| MAL Cream | 4.4 |
"Pain (11-point numeric rating scale) by PDT Session; Overall (If both areas have been treated, maximum intensity over both areas is used for analysis.) Patients assessed the pain experienced during PDT using an 11-point numeric rating pain scale (NRPS) ranging from 0 (no pain at all) to 10 (worst possible pain). This score reflects the patient's maximum pain during PDT.~Only applicable for subjects who received a retreatment (PDT-2) due to remaining lesions 12 weeks after the first treatment (PDT-1) (subjects with data)" (NCT02799069)
Timeframe: during PDT treatment [3 h - 4 h ]
| Intervention | units on a scale (Mean) |
|---|---|
| Vehicle | 0.3 |
| BF-200 ALA | 3.1 |
| MAL Cream | 3.3 |
A complete responder was defined as a subject in whom all treated lesions were cleared (all lesions showing complete remission) at 12 weeks after the first PDT. (NCT02799069)
Timeframe: 12 weeks after the first PDT
| Intervention | percentage of patients (Number) |
|---|---|
| Vehicle | 3.9 |
| BF-200 ALA | 48.4 |
| MAL Cream | 37.0 |
A complete responder was defined as a subject in whom all treated lesions were cleared (all lesions showing complete remission) at 12 weeks after the second PDT. A second PDT was applied in case partial- or non-responding lesions remained 12 weeks after the first PDT. (NCT02799069)
Timeframe: 12 weeks after the second PDT, 24 weeks after first treatment
| Intervention | percentage of patients (Number) |
|---|---|
| Vehicle | 13.7 |
| BF-200 ALA | 57.8 |
| MAL Cream | 43.2 |
"Subgroup analysis of patients treated with a narrow spectrum device for PDT Illumination (~630 nm).~An overall complete responder was defined as a subject in whom all treated lesions were cleared (all lesions showing complete remission) 12 weeks after the last PDT.~The outcome measure considered complete responders who were completely cleared 12 weeks after the first PDT and responders who were completely cleared 12 weeks after the second PDT if a re-treatment was necessary (in case of partial- or non-responding lesions 12 weeks after the first PDT)" (NCT02799069)
Timeframe: 12 weeks after the last PDT, up to 24 weeks after the first treatment
| Intervention | percentage of patients (Number) |
|---|---|
| Vehicle | 12.8 |
| BF-200 ALA | 84.8 |
| MAL Cream | 67.5 |
"An overall complete responder was defined as a subject in whom all treated lesions were cleared (all lesions showing complete remission) 12 weeks after the last PDT.~The outcome measure considered complete responders who were completely cleared 12 weeks after the first PDT and responders who were completely cleared 12 weeks after the second PDT if a re-treatment was necessary (in case of partial- or non-responding lesions 12 weeks after the first PDT)" (NCT02799069)
Timeframe: 12 weeks after the last PDT, up to 24 weeks after the first treatment
| Intervention | percentage of patients (Number) |
|---|---|
| Vehicle | 17.1 |
| BF-200 ALA | 78.2 |
| MAL Cream | 64.2 |
"An overall complete responder was defined as a subject in whom all treated lesions were cleared (all lesions showing complete remission) 12 weeks after the last PDT.~The outcome measure considered complete responders who were completely cleared 12 weeks after the first PDT and responders who were completely cleared 12 weeks after the second PDT if a re-treatment was necessary (in case of partial- or non-responding lesions 12 weeks after the first PDT)" (NCT02799069)
Timeframe: 12 weeks after the last PDT, up to 24 weeks after the first treatment
| Intervention | percentage of patients (Number) |
|---|---|
| Vehicle | 20.0 |
| BF-200 ALA | 79.4 |
| MAL Cream | 65.3 |
A complete responder was defined as a subject in whom all treated lesions were cleared (all lesions showing complete remission) at 3-4 weeks after the first PDT. (NCT02799069)
Timeframe: 3-4 weeks after the first PDT
| Intervention | percentage of patients (Number) |
|---|---|
| Vehicle | 2.6 |
| BF-200 ALA | 34.7 |
| MAL Cream | 24.8 |
A complete responder at week 3-4 after treatment was defined as a subject in whom all treated lesions were cleared (all lesions showing complete remission). This outcome measure considered patients who were completely cleared at 3-4 weeks after the last PDT which included complete responders 3-4 weeks after the first and complete responders 3-4 weeks after the second PDT ( a second PDT was applied in case of remaining lesions 12 weeks after the first PDT). (NCT02799069)
Timeframe: 3-4 weeks after the last PDT, up to 16 weeks after the first treatment
| Intervention | percentage of patients (Number) |
|---|---|
| Vehicle | 14.5 |
| BF-200 ALA | 54.0 |
| MAL Cream | 43.9 |
A complete responder was defined as a subject in whom all treated lesions were cleared (all lesions showing complete remission) at 3-4 weeks after the second PDT. A second PDT was applied in case partial- or non-responding lesions remained 12 weeks after the first PDT. (NCT02799069)
Timeframe: 3-4 weeks after the second PDT, 15-16 weeks after first treatment
| Intervention | percentage of patients (Number) |
|---|---|
| Vehicle | 13.7 |
| BF-200 ALA | 48.4 |
| MAL Cream | 43.9 |
"A partial responder was defined as a subject in whom at least 75% of the treated lesions were cleared (lesions showing complete remission). This outcome measure considers partial responders at 12 weeks after last PDT.~The outcome measure combined partial responders with at least 75% of lesions cleared at 12 weeks after the first PDT and after the second PDT (a second PDT was applied in case of partial- or non-responding lesions 12 weeks after the first PDT) ." (NCT02799069)
Timeframe: 12 weeks after the last PDT, up to 24 weeks after first treatment
| Intervention | percentage of patients (Number) |
|---|---|
| Vehicle | 26.3 |
| BF-200 ALA | 87.1 |
| MAL Cream | 78.0 |
A partial responder was defined as a subject in whom at least 75% of the treated lesions were cleared (lesions showing complete remission). This outcome measure considers partial responders at 12 weeks after the first PDT. (NCT02799069)
Timeframe: 12 weeks after the first PDT
| Intervention | percentage of patients (Number) |
|---|---|
| Vehicle | 13.2 |
| BF-200 ALA | 58.9 |
| MAL Cream | 53.3 |
"A partial responder was defined as a subject in whom at least 75% of the treated lesions were cleared (lesions showing complete remission). This outcome measure considers partial responders at 12 weeks after the second PDT.~A second PDT was applied in case of partial- or non-responding lesions 12 weeks after the first PDT." (NCT02799069)
Timeframe: 12 weeks after the second PDT, 24 weeks after first treatment
| Intervention | percentage of patients (Number) |
|---|---|
| Vehicle | 23.3 |
| BF-200 ALA | 73.4 |
| MAL Cream | 65.2 |
A partial responder was defined as a subject in whom at least 75% of the treated lesions were cleared (lesions showing complete remission). This outcome measure considers partial responders at 3-4 weeks after the first PDT. (NCT02799069)
Timeframe: 3-4 weeks after the first PDT
| Intervention | percentage of patients (Number) |
|---|---|
| Vehicle | 2.6 |
| BF-200 ALA | 50.0 |
| MAL Cream | 45.9 |
"A partial responder was defined as a subject in whom at least 75% of the treated lesions were cleared (lesions showing complete remission). This outcome measure considers partial responders at 3-4 weeks after last PDT.~The outcome measure combined partial responders with at least 75% of lesions cleared at 3-4 weeks after the first PDT or after the second PDT (a second PDT was applied in case of partial- or non-responding lesions 12 weeks after the first PDT)." (NCT02799069)
Timeframe: 3-4 weeks after the last PDT, up to 16 weeks after the first treatment
| Intervention | percentage of patients (Number) |
|---|---|
| Vehicle | 21.1 |
| BF-200 ALA | 70.6 |
| MAL Cream | 64.6 |
"A partial responder was defined as a subject in whom at least 75% of the treated lesions were cleared (lesions showing complete remission). This outcome measure considers partial responders at 3-4 weeks after the second PDT.~A second PDT was applied in case of partial- or non-responding lesions 12 weeks after the first PDT." (NCT02799069)
Timeframe: 3-4 weeks after the second PDT, 15-16 weeks after first treatment
| Intervention | percentage of patients (Number) |
|---|---|
| Vehicle | 20.5 |
| BF-200 ALA | 68.0 |
| MAL Cream | 62.6 |
"Adverse reactions are Treatment-Emergent Adverse Events considered at least possibly related to the treatment with the randomized investigational medicinal products; Adverse reactions are shown with a frequency cut off of >=5%.~TEAEs are considered from subjects who received only one PDT or subjects who received 2 PDTs (initial Treatment (PDT-1) and retreatment (PDT-2) due to remaining lesions 12 weeks after first photodynamic therapy.~The safety set consists of all patients treated at least once with investigational product. Treatment with investigational product consists of application of study drug followed by illumination. This excludes one patient from the safety set; for this patient the investigational product was applied on the skin but it was not illuminated. Patients are treated according to actual treatment." (NCT02799069)
Timeframe: up to 12 weeks after the last PDT, up to 24 weeks after first treatment
| Intervention | Participants (Count of Participants) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Application site irritation | Application site erythema | Application site pain | Application site edema | Application site pruritus | Application site exfoliation | Application site scab | Application site induration | Application site vesicles | Application site paraesthesia | Skin exfoliation | |
| BF-200 ALA | 219 | 198 | 175 | 62 | 59 | 44 | 27 | 24 | 22 | 17 | 17 |
| MAL Cream | 222 | 199 | 179 | 61 | 60 | 44 | 30 | 21 | 23 | 18 | 15 |
| Vehicle | 25 | 31 | 19 | 1 | 6 | 5 | 2 | 0 | 1 | 2 | 1 |
Local discomfort reported by the patients during Illumination of first PDT (PDT1) (NCT02799069)
Timeframe: during PDT treatment [3 h - 4 h ]
| Intervention | percentage of patients (Number) | |
|---|---|---|
| Itching during PDT-1 | Burning during PDT-1 | |
| BF-200 ALA | 9.7 | 81.9 |
| MAL Cream | 14.6 | 85.8 |
| Vehicle | 2.6 | 28.9 |
Local discomfort reported by the patients during Illumination phase of retreatment (PDT-2); only applicable for subjects who received a retreatment (PDT-2) due to remaining lesions 12 weeks after the first treatment (PDT-1) (subjects with data) (NCT02799069)
Timeframe: during PDT treatment [3 h - 4 h ]
| Intervention | percentage of patients (Number) | |
|---|---|---|
| Itching during PDT-2 | Burning during PDT-2 | |
| BF-200 ALA | 7.3 | 69.9 |
| MAL Cream | 8.7 | 74.7 |
| Vehicle | 0.0 | 14.7 |
Local skin reactions in the treatment area as assessed by the investigator during the first PDT (PDT-1) (NCT02799069)
Timeframe: during PDT treatment [3 h - 4 h ]
| Intervention | percentage of patients (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Erythema | Edema | Induration | Vesicles | Erosion | Ulceration | Scaling/Flaking | Scabbing/Crusting | Weeping/Exudate | |
| BF-200 ALA | 72.6 | 22.2 | 9.3 | 3.2 | 1.2 | 0.0 | 0.4 | 0.4 | 0.4 |
| MAL Cream | 71.1 | 23.6 | 8.5 | 6.1 | 1.2 | 0.0 | 0.0 | 0.0 | 1.2 |
| Vehicle | 32.9 | 1.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Local skin reactions in the treatment area as assessed by the investigator during PDT-2; only applicable for subjects who were retreated with a second PDT due to remaining lesions 12 weeks after the first PDT (subjects with data). (NCT02799069)
Timeframe: during PDT treatment [3 h - 4 h ]
| Intervention | percentage of patients (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Erythema | Edema | Induration | Vesicles | Erosion | Ulceration | Scaling/Flaking | Scabbing/Crusting | Weeping/Exudate | |
| BF-200 ALA | 61.8 | 10.6 | 4.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| MAL Cream | 70.0 | 11.3 | 3.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Vehicle | 19.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
The cosmetic outcome 12 weeks after the last PDT (12 weeks after 1st PDT for subjects who are completely cleared at this time point, 12 weeks after 2nd PDT for subjects retreated due to remaining lesions 12 weeks after 1st PDT) will be calculated on the basis of the skin quality assessment (skin surface, hyperpigmentation, hypopigmentation, mottled or irregular pigmentation, degree of scarring, and atrophy) upon visual examination (scale: 0= none, 1= mild, 2= moderate, 3=severe). The cosmetic outcome is rated as very good if the sum score of the previously mentioned ratings (all ratings for each sign added up) has improved by at least 2 points as compared to baseline; as good if the sum score has improved by at least 1 point as compared to baseline; as satisfactory if the sum score is identical to the one at baseline; as unsatisfactory if the sum score has worsened by 1 point compared to baseline and as impaired if the sum score has worsened by at least 2 points compared to baseline. (NCT02799069)
Timeframe: 12 weeks after the last PDT, up to 24 weeks after first treatment
| Intervention | percentage of patients (Number) | |||||
|---|---|---|---|---|---|---|
| very good or good | very good | good | Satisfactory | Unsatisfactory | Impaired | |
| BF-200 ALA | 36.0 | 16.5 | 19.4 | 55.8 | 6.6 | 1.7 |
| MAL Cream | 37.1 | 19.2 | 17.9 | 53.3 | 5.8 | 3.8 |
| Vehicle | 29.4 | 14.7 | 14.7 | 50.0 | 16.2 | 4.4 |
14 reviews available for aminolevulinic acid and Pain
| Article | Year |
|---|---|
Counteracting Side-effects of Photodynamic Therapy for Actinic Keratoses.
Topics: Aminolevulinic Acid; Drug-Related Side Effects and Adverse Reactions; Humans; Inflammation; Keratosi | 2022 |
The Interventions to Minimize Pain During Photodynamic Therapy With 5-Aminolevulinic Acid for the Treatment of Cutaneous Diseases.
Topics: Aminolevulinic Acid; Humans; Levulinic Acids; Pain; Photochemotherapy; Skin Diseases; United States | 2023 |
Segmental porokeratosis responding to methyl aminolevulinate photodynamic therapy.
Topics: Aftercare; Aged; Aminolevulinic Acid; Humans; Male; Pain; Photochemotherapy; Porokeratosis; Pruritus | 2020 |
Photodynamic therapy for aesthetic-cosmetic indications.
Topics: Aminolevulinic Acid; Humans; Keratosis, Actinic; Light; Pain; Photochemotherapy; Photosensitizing Ag | 2018 |
Pain perception during photodynamic therapy: why is daylight PDT with methyl aminolevulinate almost pain-free? A review on the underlying mechanisms, clinical reflections and resulting opportunities.
Topics: Aminolevulinic Acid; Humans; Light; Pain; Pain Perception; Photochemotherapy; Photosensitizing Agent | 2018 |
Daylight photodynamic therapy for field cancerization: lessons from molecular biology.
Topics: Aminolevulinic Acid; Carcinoma, Squamous Cell; Humans; Keratosis, Actinic; Light; Pain; Photochemoth | 2018 |
Daylight versus conventional photodynamic therapy for the treatment of actinic keratosis: A meta-analysis of randomized controlled trials.
Topics: Aminolevulinic Acid; Humans; Keratosis, Actinic; Pain; Photochemotherapy; Photosensitizing Agents; R | 2019 |
[PDT panoramic view. Principle, photosensitizers, light sources and validated indications in dermatology].
Topics: Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Clinical Trials as Topic; Humans; Kerat | 2013 |
Photodynamic therapy for actinic cheilitis: a systematic review.
Topics: Aminolevulinic Acid; Cheilitis; Esthetics; Humans; Pain; Photochemotherapy; Photosensitizing Agents; | 2015 |
Daylight PDT with MAL - current data and practical recommendations of an expert panel.
Topics: Aminolevulinic Acid; Evidence-Based Medicine; Germany; Humans; Keratosis, Actinic; Light; Pain; Phot | 2015 |
Pain associated with aminolevulinic acid-photodynamic therapy of skin disease.
Topics: Administration, Cutaneous; Aminolevulinic Acid; Analgesia; Humans; Pain; Pain Management; Photochemo | 2009 |
A review of pain experienced during topical photodynamic therapy--our experience in Dundee.
Topics: Administration, Topical; Aminolevulinic Acid; Comorbidity; Female; Humans; Male; Pain; Pain Measurem | 2011 |
[Fluorescence diagnosis of non-melanoma skin cancer].
Topics: Aminolevulinic Acid; Apoptosis; Carcinoma, Basal Cell; Carcinoma, Basosquamous; Carcinoma, Squamous | 2012 |
Pain, pain relief and other practical issues in photodynamic therapy.
Topics: Administration, Topical; Aminolevulinic Acid; Analgesia; Humans; Pain; Patient Education as Topic; P | 2005 |
62 trials available for aminolevulinic acid and Pain
| Article | Year |
|---|---|
Optimizing treatment of acne with photodynamic therapy (PDT) to achieve long-term remission and reduce side effects. A prospective randomized controlled trial.
Topics: Acne Vulgaris; Adolescent; Adult; Aminolevulinic Acid; Female; Humans; Light; Male; Pain; Photochemo | 2021 |
Combined versus conventional photodynamic therapy with 5-aminolaevulinic acid nanoemulsion (BF-200 ALA) for actinic keratosis: A randomized, single-blind, prospective study.
Topics: Aminolevulinic Acid; Humans; Keratosis, Actinic; Pain; Photochemotherapy; Photosensitizing Agents; P | 2022 |
Randomized controlled trial for evaluation of efficacy and pain during photodynamic therapy for actinic keratosis of face and scalp comparing two irradiation protocols.
Topics: Aminolevulinic Acid; Face; Humans; Keratosis, Actinic; Pain; Photochemotherapy; Photosensitizing Age | 2022 |
Ablative Fractional Laser-assisted Low-irradiance Photodynamic Therapy for Treatment of Actinic Keratoses in Organ Transplant Recipients: A Prospective, Randomized, Intraindividual Controlled Trial.
Topics: Aminolevulinic Acid; Humans; Keratosis, Actinic; Lasers; Organ Transplantation; Pain; Photochemother | 2022 |
Hemodynamic changes during conventional and daylight photodynamic therapy of actinic keratoses - a randomized controlled trial.
Topics: Aminolevulinic Acid; Hemodynamics; Humans; Hypertension; Keratosis, Actinic; Pain; Photochemotherapy | 2022 |
Efficacy of two different methods of cold air analgesia for pain relief in PDT of actinic keratoses of the head region - a randomized controlled comparison study.
Topics: Aminolevulinic Acid; Humans; Keratosis, Actinic; Pain; Photochemotherapy; Photosensitizing Agents; S | 2022 |
Plum-blossom needle tapping enhances the efficacy of ALA photodynamic therapy for facial actinic keratosis in Chinese population: a randomized, multicenter, prospective, and observer-blind study.
Topics: Acupuncture Therapy; Administration, Cutaneous; Aminolevulinic Acid; Dry Needling; East Asian People | 2023 |
A regimen to minimize pain during blue light photodynamic therapy of actinic keratoses: Bilaterally controlled, randomized trial of simultaneous versus conventional illumination.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Drug Administration Schedule; Facial Dermatoses; Femal | 2020 |
Modified 5-aminolevulinic acid photodynamic therapy to reduce pain in the treatment of moderate to severe acne vulgaris: A prospective, randomized, split-face study.
Topics: Acne Vulgaris; Aminolevulinic Acid; Humans; Pain; Photochemotherapy; Photosensitizing Agents; Prospe | 2021 |
Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria.
Topics: Acetylgalactosamine; Adult; Aminolevulinic Acid; Double-Blind Method; Fatigue; Female; Humans; Injec | 2020 |
Modified photodynamic therapy to minimize pain in the treatment of condylomata acuminata: A prospective, randomized, self-controlled study.
Topics: Aminolevulinic Acid; Condylomata Acuminata; Humans; Pain; Photochemotherapy; Photosensitizing Agents | 2020 |
Three-step irradiance schedule versus two-step irradiance schedule for pain control during topical 5-aminolevulinic acid-photodynamic therapy of facial acne in Chinese patients: A prospective randomized comparative study.
Topics: Acne Vulgaris; Aminolevulinic Acid; China; Humans; Pain; Photochemotherapy; Photosensitizing Agents; | 2022 |
Randomized, Controlled Trial of Fractional Carbon Dioxide Laser Resurfacing Followed by Ultrashort Incubation Aminolevulinic Acid Blue Light Photodynamic Therapy for Actinic Keratosis.
Topics: Aminolevulinic Acid; Erythema; Esthetics; Follow-Up Studies; Humans; Hyperpigmentation; Keratosis, A | 2017 |
Effect of Expedited Microneedle-Assisted Photodynamic Therapy for Field Treatment of Actinic Keratoses: A Randomized Clinical Trial.
Topics: Aged; Aminolevulinic Acid; Female; Humans; Keratosis, Actinic; Male; Middle Aged; Needles; Pain; Pai | 2017 |
Photodynamic therapy is more effective than imiquimod for actinic keratosis in organ transplant recipients: a randomized intraindividual controlled trial.
Topics: Aged; Aminolevulinic Acid; Drug Eruptions; Facial Dermatoses; Female; Hand Dermatoses; Humans; Imiqu | 2018 |
Treatment of superficial basal cell carcinoma by topical photodynamic therapy with fractionated 5-aminolaevulinic acid 20% vs. two-stage topical methyl aminolaevulinate: results of a randomized controlled trial.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cel | 2018 |
A randomized split-scalp study comparing calcipotriol-assisted methyl aminolaevulinate photodynamic therapy (MAL-PDT) with conventional MAL-PDT for the treatment of actinic keratosis.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Calcitriol; Dermatologic Agents; Drug Therapy, Combina | 2018 |
The efficacy and tolerability of 5-aminolevulinic acid 5% thermosetting gel photodynamic therapy (PDT) in the treatment of mild-to-moderate acne vulgaris. A two-center, prospective assessor-blinded, proof-of-concept study.
Topics: Acne Vulgaris; Adolescent; Adult; Aminolevulinic Acid; Facial Dermatoses; Female; Gels; Humans; Male | 2019 |
Treatment of Actinic Keratosis with Photodynamic Therapy Using Red or Green Light: A Comparative Study.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Aminolevulinic Acid; Female; Humans; Keratosis, | 2018 |
A randomized intraindividual comparative study of methyl-5-aminolaevulinate vs. 5-aminolaevulinic acid nanoemulsion (BF-200 ALA) in photodynamic therapy for actinic keratosis of the face and scalp.
Topics: Administration, Cutaneous; Aged; Aminolevulinic Acid; Erythema; Face; Female; Humans; Keratosis, Act | 2018 |
Single versus two-treatment schedule of methyl aminolevulinate daylight photodynamic therapy for actinic keratosis of the face and scalp: An intra-patient randomized trial.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Drug Administration Schedule; Face; Female; Humans; Ke | 2019 |
Dermatology life quality index and side effects after topical photodynamic therapy of actinic keratosis.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Edema; Erythema; Facial Dermatoses; Female; Humans; Ke | 2013 |
Pain during topical photodynamic therapy of actinic keratoses with 5-aminolevulinic acid and red light source: randomized controlled trial.
Topics: Aged; Aminolevulinic Acid; Animals; Face; Female; Humans; Male; Pain; Pain Measurement; Photochemoth | 2013 |
Red light ALA-PDT for large areas of actinic keratosis is limited by severe pain and patient dissatisfaction.
Topics: Aminolevulinic Acid; Female; Humans; Keratosis, Actinic; Male; Pain; Photochemotherapy; Photosensiti | 2013 |
Correlations between photoactivable porphyrins' fluorescence, erythema and the pain induced by PDT on normal skin using ALA-derivatives.
Topics: Adult; Aminolevulinic Acid; Dose-Response Relationship, Radiation; Erythema; Fluorescence; Humans; M | 2013 |
A randomized, double-blind, placebo-controlled study of oral oxycodone plus acetaminophen for the treatment of pain in photodynamic therapy on port wine stains.
Topics: Acetaminophen; Administration, Oral; Adolescent; Adult; Aminolevulinic Acid; Analgesics, Non-Narcoti | 2014 |
Two-step irradiance schedule versus single-dose tramadol sustained-release tablets for pain control during topical 5-aminolevulinic acid-photodynamic therapy of condyloma acuminatum in Chinese patients: a randomized comparative study.
Topics: Adult; Aminolevulinic Acid; Analgesics, Opioid; China; Condylomata Acuminata; Delayed-Action Prepara | 2014 |
Daylight photodynamic therapy with methyl aminolevulinate cream as a convenient, similarly effective, nearly painless alternative to conventional photodynamic therapy in actinic keratosis treatment: a randomized controlled trial.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Aminolevulinic Acid; Facial Dermatoses; Female; | 2014 |
Combination of ablative fractional laser and daylight-mediated photodynamic therapy for actinic keratosis in organ transplant recipients - a randomized controlled trial.
Topics: Aged; Aminolevulinic Acid; Combined Modality Therapy; Female; Humans; Keratosis, Actinic; Laser Ther | 2015 |
Topical corticosteroid reduces inflammation without compromising the efficacy of photodynamic therapy for actinic keratoses: a randomized clinical trial.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Aminolevulinic Acid; Anti-Inflammatory Agents; C | 2014 |
Comparing cold-air analgesia, systemically administered analgesia and scalp nerve blocks for pain management during photodynamic therapy for actinic keratosis of the scalp presenting as field cancerization: a randomized controlled trial.
Topics: Administration, Oral; Aged; Aminolevulinic Acid; Analgesia; Analgesics, Opioid; Analysis of Variance | 2015 |
Safety of Novel Amino-5-laevulinate Photosensitizer Precursors in Photodynamic Therapy for Healthy Human Skin.
Topics: Administration, Cutaneous; Adult; Aminolevulinic Acid; Double-Blind Method; Erythema; Healthy Volunt | 2016 |
Daylight photodynamic therapy with methyl aminolevulinate cream is effective and nearly painless in treating actinic keratoses: a randomised, investigator-blinded, controlled, phase III study throughout Europe.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Europe; Facial Dermatoses; Female; Humans; Keratosis, | 2015 |
Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy.
Topics: Aminolevulinic Acid; Biomarkers; Dose-Response Relationship, Drug; Erythema; Female; Humans; Keratos | 2015 |
Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy.
Topics: Aminolevulinic Acid; Biomarkers; Dose-Response Relationship, Drug; Erythema; Female; Humans; Keratos | 2015 |
Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy.
Topics: Aminolevulinic Acid; Biomarkers; Dose-Response Relationship, Drug; Erythema; Female; Humans; Keratos | 2015 |
Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy.
Topics: Aminolevulinic Acid; Biomarkers; Dose-Response Relationship, Drug; Erythema; Female; Humans; Keratos | 2015 |
Laser-mediated Photodynamic Therapy: An Alternative Treatment for Actinic Keratosis?
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Female; Humans; Keratosis, Actinic; Lasers, Dye; Low-L | 2016 |
Photodynamic therapy with methyl aminolaevulinate 80 mg g(-1) for severe facial acne vulgaris: a randomized vehicle-controlled study.
Topics: Acne Vulgaris; Administration, Cutaneous; Adolescent; Adult; Aminolevulinic Acid; Child; Double-Blin | 2016 |
Pulse photodynamic therapy reduces inflammation without compromising efficacy in the treatment of multiple mild actinic keratoses of the face and scalp: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Erythema; Facial Dermatoses; Female; Fluorescence; Hum | 2016 |
Randomized Vehicle-Controlled Study of Short Drug Incubation Aminolevulinic Acid Photodynamic Therapy for Actinic Keratoses of the Face or Scalp.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Erythema; Facial Dermatoses; Female; Humans; Ke | 2016 |
Increased protoporphyrin IX accumulation does not improve the effect of photodynamic therapy for actinic keratosis: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Curettage; Drug Eruptions; Erythema; Female; Fluoresce | 2017 |
Microneedle-assisted incubation during aminolaevulinic acid photodynamic therapy of actinic keratoses: a randomized controlled evaluator-blind trial.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Equipment Design; Facial Dermatoses; Female; Forehead; | 2017 |
Randomized controlled trial comparing 35% trichloroacetic acid peel and 5-aminolaevulinic acid photodynamic therapy for treating multiple actinic keratosis.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Caustics; Facial Dermatoses; Female; Humans; Keratosis | 2017 |
Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Dose-Response Relationsh | 2008 |
Phototoxic reactions in healthy volunteers following photodynamic therapy with methylaminolevulinate cream or with cream containing 5-aminolevulinic acid: a phase II, randomized study.
Topics: Administration, Topical; Aminolevulinic Acid; Area Under Curve; Humans; Pain; Photochemotherapy; Pho | 2009 |
Photodynamic therapy of multiple actinic keratoses: reduced pain through use of visible light plus water-filtered infrared A compared with light from light-emitting diodes.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Double-Blind Method; Female; Filtration; Humans; Infra | 2010 |
Microneedle pre-treatment of human skin improves 5-aminolevulininc acid (ALA)- and 5-aminolevulinic acid methyl ester (MAL)-induced PpIX production for topical photodynamic therapy without increase in pain or erythema.
Topics: Administration, Cutaneous; Adult; Aminolevulinic Acid; Erythema; Female; Humans; Light; Male; Needle | 2010 |
[Photodynamic therapy for acne: use of the pulsed dye laser and methylaminolevulinate].
Topics: Acne Vulgaris; Adolescent; Aminolevulinic Acid; Combined Modality Therapy; Facial Dermatoses; Female | 2010 |
Safety and efficacy comparison of blue versus red light sources for photodynamic therapy using methyl aminolevulinate in photodamaged skin.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cohort Studies; Erythema; Female; Humans; Light | 2011 |
The impact of different fluence rates on pain and clinical outcome in patients with actinic keratoses treated with photodynamic therapy.
Topics: Adult; Aged; Aminolevulinic Acid; Female; Follow-Up Studies; Humans; Keratosis, Actinic; Male; Middl | 2011 |
Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Female; | 2012 |
Intensified photodynamic therapy of actinic keratoses with fractional CO2 laser: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Humans; Keratosis, Actinic; Laser Therapy; Lasers, Gas | 2012 |
Intensified photodynamic therapy of actinic keratoses with fractional CO2 laser: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Humans; Keratosis, Actinic; Laser Therapy; Lasers, Gas | 2012 |
Intensified photodynamic therapy of actinic keratoses with fractional CO2 laser: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Humans; Keratosis, Actinic; Laser Therapy; Lasers, Gas | 2012 |
Intensified photodynamic therapy of actinic keratoses with fractional CO2 laser: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Humans; Keratosis, Actinic; Laser Therapy; Lasers, Gas | 2012 |
Acne treatment by methyl aminolevulinate photodynamic therapy with red light vs. intense pulsed light.
Topics: Acne Vulgaris; Adult; Aminolevulinic Acid; Color; Female; Humans; Intense Pulsed Light Therapy; Male | 2013 |
Pain associated with photodynamic therapy using 5-aminolevulinic acid or 5-aminolevulinic acid methylester on tape-stripped normal skin.
Topics: Adult; Aminolevulinic Acid; Double-Blind Method; Esterification; Female; Humans; Male; Methyl Ethers | 2003 |
Photodynamic therapy of actinic keratosis at varying fluence rates: assessment of photobleaching, pain and primary clinical outcome.
Topics: Aged; Aminolevulinic Acid; Dose-Response Relationship, Radiation; Female; Humans; Keratosis; Male; M | 2004 |
In vitro and in vivo comparison of two different light sources for topical photodynamic therapy.
Topics: Adult; Aged; Aminolevulinic Acid; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; | 2006 |
Photodynamic therapy of acne vulgaris using methyl aminolaevulinate: a blinded, randomized, controlled trial.
Topics: Acne Vulgaris; Adult; Aminolevulinic Acid; Double-Blind Method; Female; Humans; Male; Pain; Photoche | 2006 |
Photodynamic therapy induces less pain in patients treated with methyl aminolevulinate compared to aminolevulinic acid.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Female; Humans; Keratosis; Male; Middle Aged; Ointment | 2006 |
Morphine gel 0.3% does not relieve pain during topical photodynamic therapy: a randomized, double-blind, placebo-controlled study.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Double-Blind Method; Gel | 2006 |
Effect of subcutaneous infiltration anesthesia on pain in photodynamic therapy: a controlled open pilot trial.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Anesthesia, Local; Female; Gels; Humans; Keratosis; Ma | 2007 |
Randomized, double-blind, prospective study to compare topical 5-aminolaevulinic acid methylester with topical 5-aminolaevulinic acid photodynamic therapy for extensive scalp actinic keratosis.
Topics: Administration, Topical; Aged; Aged, 80 and over; Aminolevulinic Acid; Double-Blind Method; Humans; | 2007 |
Long-pulsed dye laser versus long-pulsed dye laser-assisted photodynamic therapy for acne vulgaris: A randomized controlled trial.
Topics: Acne Vulgaris; Adult; Aminolevulinic Acid; Edema; Erythema; Female; Fluorescence; Humans; Laser Ther | 2008 |
Photodynamic therapy for superficial bladder cancer under local anaesthetic.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Anesthesia, Local; Anesthetics, Local; Carcinoma, Tran | 2002 |
Photodynamic therapy for severe facial acne vulgaris with 5% 5-aminolevulinic acid vs 10% 5-aminolevulinic acid: A split-face randomized controlled study.
Topics: Acne Vulgaris; Administration, Cutaneous; Adult; Aminolevulinic Acid; Dose-Response Relationship, Dr | 2020 |
44 other studies available for aminolevulinic acid and Pain
| Article | Year |
|---|---|
No room for pain: A prospective study showing effective and nearly pain-free treatment of actinic keratosis with simulated daylight photodynamic therapy (SDL-PDT) using the IndoorLux® System in combination with BF-200 ALA (Ameluz®).
Topics: Aminolevulinic Acid; Humans; Keratosis, Actinic; Pain; Photochemotherapy; Photosensitizing Agents; P | 2022 |
Pulse rate and blood pressure changes during low-irradiance PDT compared with conventional PDT in the treatment of facial actinic keratoses: A retrospective study.
Topics: Aminolevulinic Acid; Blood Pressure; Heart Rate; Humans; Hypertension; Keratosis, Actinic; Pain; Pho | 2022 |
A prospective study of adverse reactions of ALA-PDT for acne vulgaris.
Topics: Acne Vulgaris; Aminolevulinic Acid; China; Female; Humans; Hyperpigmentation; Male; Pain; Photochemo | 2022 |
Dezocine effectively alleviates the pain during topical 5-aminolaevulinic acid photodynamic therapy for condyloma acuminatum.
Topics: Aminolevulinic Acid; Condylomata Acuminata; Humans; Pain; Photochemotherapy | 2022 |
RNA interference therapy in acute hepatic porphyrias.
Topics: Aminolevulinic Acid; Heme; Humans; Pain; Porphyrias; Porphyrias, Hepatic; Quality of Life; RNA Inter | 2023 |
An audit of pain scores with conventional and white light topical 5-methyl aminolaevulinic acid photodynamic therapy for superficial basal cell carcinoma and squamous cell carcinoma in situ.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Femal | 2020 |
Combined daylight and conventional photodynamic therapy with 5-aminolaevulinic acid nanoemulsion (BF-200 ALA) for actinic keratosis of the face and scalp: a new and efficient approach.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Face; Female; Humans; Keratosis, Actinic; Light; Male; | 2020 |
Two-step irradiance provides less pain with similar efficacy in photodynamic therapy on chinese patients with moderate to severe acne.
Topics: Acne Vulgaris; Aminolevulinic Acid; China; Humans; Pain; Photochemotherapy; Photosensitizing Agents; | 2021 |
Field cancerization treatment: Adjustments to an ALA red light photodynamic therapy protocol to improve pain tolerance.
Topics: Aminolevulinic Acid; Humans; Keratosis, Actinic; Pain; Photochemotherapy; Photosensitizing Agents; T | 2021 |
[Successful treatment of cutaneous leishmaniasis with simulated daylight photodynamic therapy].
Topics: Aminolevulinic Acid; Child, Preschool; Humans; Leishmania tropica; Leishmaniasis, Cutaneous; Male; P | 2022 |
Efficacy and tolerance of photodynamic therapy for vulvar Paget's disease: a multicentric retrospective study.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Female; Follow-Up Studies; Humans; Middle Aged; Neopla | 2018 |
Pain and stinging associated with pretreatment in photodynamic therapy of actinic keratosis.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Female; Humans; Keratosis, Actinic; Male; Middle Aged; | 2019 |
Thermal Photodynamic Therapy for Actinic Keratoses on Facial Skin: A Proof-of-Concept Study.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Aminolevulinic Acid; Facial Dermatoses; Hot Temp | 2019 |
Risk of acute postoperative hypertension after topical photodynamic therapy for non-melanoma skin cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Aminolevulinic Acid; Blood Pressure; Bowen's Disease; Carcinom | 2013 |
Post procedural pain with photodynamic therapy is more severe than skin surgery.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Analgesics; Facial Neoplasms; Female; Humans; M | 2015 |
Correlation between protoporphyrin IX fluorescence intensity, photobleaching, pain and clinical outcome of actinic keratosis treated by photodynamic therapy.
Topics: Aged; Aminolevulinic Acid; Fluorescence; Humans; Keratosis, Actinic; Middle Aged; Pain; Pain Measure | 2013 |
Temperature-modulated photodynamic therapy for the treatment of actinic keratosis on the extremities: a pilot study.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Blister; Clinical Protocols; Erythema; Extremities; Fe | 2014 |
A study of topical methyl-aminolaevulinate red-light photodynamic therapy in the treatment of actinic keratosis in Chinese patients: a Singaporean experience.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Asian People; Female; Humans; Keratosis, Actinic; Male | 2015 |
Conventional vs. daylight methyl aminolevulinate photodynamic therapy for actinic keratosis of the face and scalp: an intra-patient, prospective, comparison study in Italy.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Facial Dermatoses; Female; Humans; Italy; Keratosis, A | 2015 |
Correlation between treatment time, photobleaching, inflammation and pain after photodynamic therapy with methyl aminolevulinate on tape-stripped skin in healthy volunteers.
Topics: Adult; Aminolevulinic Acid; Erythema; Fluorescence; Forearm; Humans; Inflammation; Male; Middle Aged | 2015 |
[Not Available].
Topics: Aminolevulinic Acid; Evidence-Based Medicine; Humans; Keratosis, Actinic; Pain; Photochemotherapy; P | 2015 |
[Procedure for daylight methyl aminolevulinate photodynamic therapy to treat actinic keratoses].
Topics: Aminolevulinic Acid; Clinical Protocols; Facial Dermatoses; Humans; Keratosis, Actinic; Pain; Patien | 2016 |
Factors predicting pain and effect of oral analgesia in topical photodynamic therapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Analgesics; Bowen's Disea | 2017 |
Photodynamic Therapy Effectively Treats Actinic Keratoses Without Pre-Illumination Incubation Time.
Topics: Aminolevulinic Acid; Face; Humans; Keratosis, Actinic; Male; Middle Aged; Pain; Photochemotherapy; P | 2017 |
Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Huma | 2008 |
Methyl-aminolevulinate photodynamic therapy for the treatment of actinic keratoses and non-melanoma skin cancers: a retrospective analysis of response in 462 patients.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Carcinoma, Squ | 2009 |
Topical photodynamic therapy with porphyrin precursors--assessment of treatment-associated pain in a retrospective study.
Topics: Age Factors; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Humans; Ke | 2009 |
Topical aminolaevulinic acid- and aminolaevulinic acid methyl ester-based photodynamic therapy with red and violet light: influence of wavelength on pain and erythema.
Topics: Administration, Topical; Adult; Aminolevulinic Acid; Animals; Erythema; Humans; Lasers; Mice; Mice, | 2009 |
Cordectomy as final treatment option for diffuse intramedullary malignant glioma using 5-ALA fluorescence-guided resection.
Topics: Adult; Aminolevulinic Acid; Astrocytoma; Cordotomy; Female; Humans; Magnetic Resonance Imaging; Neur | 2010 |
Factors influencing pain intensity during topical photodynamic therapy of complete cosmetic units for actinic keratoses.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cosmetic Techniques; Female; Humans; Keratosis, | 2010 |
Treatment with 5-aminolaevulinic acid methylester is less painful than treatment with 5-aminolaevulinic acid nanoemulsion in topical photodynamic therapy for actinic keratosis.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Emulsions; Female; Humans; Keratosis, Actinic; | 2011 |
Photodynamic therapy of non-melanoma skin cancer with methyl aminolaevulinate is associated with less pain than with aminolaevulinic acid.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Analysis of Variance; Bowen's Disease; Carcinom | 2012 |
Is the pain of topical photodynamic therapy with methyl aminolevulinate any different from that with 5-aminolaevulinic acid?
Topics: Administration, Topical; Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Humans; Male; | 2012 |
A retrospective review of pain control by a two-step irradiance schedule during topical ALA-photodynamic therapy of non-melanoma skin cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal C | 2013 |
Methyl aminolaevulinate photodynamic therapy in practice: treatment protocol.
Topics: Administration, Topical; Aminolevulinic Acid; Clinical Protocols; Dose-Response Relationship, Drug; | 2005 |
Clinical and research applications of photodynamic therapy in dermatology: experience of the Scottish PDT Centre.
Topics: Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Humans; Keratosis; Neoplasm Recurrence, | 2006 |
Pain and photodynamic therapy.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Female; Humans; Male; Middle Aged; Pain; Pain Measurem | 2007 |
Transcutaneous electrical nerve stimulation for pain relief during photodynamic therapy of actinic keratoses.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Humans; Keratosis; Male; Middle Aged; Pain; Pain Measu | 2008 |
Neuropharmacology of delta-aminolaevulinic acid. II. Effect of chronic administration in mice.
Topics: Aminolevulinic Acid; Animals; Behavior, Animal; Disease Models, Animal; Levulinic Acids; Male; Mice; | 1984 |
Primary clinical response and long-term follow-up of solar keratoses treated with topically applied 5-aminolevulinic acid and irradiation by different wave bands of light.
Topics: Administration, Topical; Aged; Aged, 80 and over; Aminolevulinic Acid; Erythema; Female; Fluorescenc | 1997 |
Photodynamic therapy of lower genital tract neoplasia.
Topics: Aminolevulinic Acid; Female; Genital Neoplasms, Female; Humans; Pain; Photochemotherapy; Photosensit | 2002 |
Lead and morbidity: A dose-response relationship.
Topics: Abdomen; Aminolevulinic Acid; Constipation; Dose-Response Relationship, Drug; Fatigue; Hematocrit; H | 1978 |
Acute intermittent porphyria. A perplexing case.
Topics: Acute Disease; Aminolevulinic Acid; Female; Humans; Middle Aged; Nervous System Diseases; Pain; Porp | 1992 |
Neurologic crises in hereditary tyrosinemia.
Topics: Acute Disease; Adolescent; Adult; Amino Acid Metabolism, Inborn Errors; Aminolevulinic Acid; Child; | 1990 |